Search Result
Results for "
glucose uptake
" in MedChemExpress (MCE) Product Catalog:
1
Biochemical Assay Reagents
5
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-116215
-
|
|
Fluorescent Dye
|
Others
|
|
2-NBDG is a fluorescently-labeled deoxyglucose analog that is used primarily to directly monitor glucose uptake by living cells and tissues. It is also used as a topical contrast reagent for the detection of neoplasia. 2-NBDG can be used in real-time confocal, high-resolution, or wide-field fluorescence microscopy as well as in flow cytometry. The probe can be excited by the Argon laser at 488 nm to give the environment-sensitive fluorescence. It has lower photostability than the rhodamine-based fluorescent probes.
|
-
-
- HY-101903
-
|
|
FABP
|
Cardiovascular Disease
Metabolic Disease
|
|
BMS-309403 is a potent, orally active and selective adipocyte fatty acid binding protein (also known as FABP4, aP2) inhibitor with Kis of <2, 250, and 350 nM for FABP4, FABP3, and FABP5, respectively. BMS-309403 interacts with the fatty-acid-binding pocket within the interior of the protein and competitively inhibits the binding of endogenous fatty acids. BMS-309403 improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells .
|
-
-
- HY-N0457
-
|
Cichoric acid; Dicaffeoyltartaric acid
|
Reactive Oxygen Species (ROS)
Apoptosis
|
Metabolic Disease
Inflammation/Immunology
|
|
Chicoric acid (Cichoric acid), an orally active dicaffeyltartaric acid, induces reactive oxygen species (ROS) generation. Chicoric acid inhibits cell viability and induces mitochondria-dependent apoptosis in 3T3-L1 preadipocytes through ROS-mediated PI3K/Akt and MAPK signaling pathways. Chicoric acid increases glucose uptake, improves insulin resistance, and attenuates glucosamine-induced inflammation. Chicoric acid has antidiabetic properties and antioxidant, anti-inflammatory effects .
|
-
-
- HY-19824
-
|
|
Autophagy
|
Cancer
|
|
3PO is an inhibitor of PFKFB3. 3PO attenuates the proliferation of several cancer cell lines with IC50s of 1.4-24 μmol/L. 3PO suppresses glucose uptake and decreases the intracellular concentration of Fru-2,6-BP, lactate, ATP, NAD + and NADH. 3PO can be used for the research of cancer .
|
-
-
- HY-W040127
-
|
|
Insulin Receptor
|
Metabolic Disease
|
|
Peonidin 3-O-glucoside chloride is an agonist of the free fatty acid receptor FFAR1 and Glucokinase. Peonidin 3-O-glucoside chloride enhances insulin secretion of pancreatic beta cells and increases glucose uptake by liver cells. Peonidin 3-O-glucoside chloride activates FFAR1, promotes the phosphorylation of related proteins in the insulin secretion pathway, and increases the expression of FFAR1. In liver cells, Peonidin 3-O-glucoside chloride activates GK and regulates proteins associated with carbohydrate metabolism. Peonidin 3-O-glucoside chloride can be used in diabetes research .
|
-
-
- HY-101903A
-
|
|
FABP
|
Cardiovascular Disease
Metabolic Disease
|
|
BMS-309403 sodium is a potent, orally active, and selective adipocyte fatty acid binding protein (also known as FABP4, aP2) inhibitor, with Kis of <2, 250, and 350 nM for FABP4, FABP3, and FABP5, respectively. BMS-309403 sodium interacts with the fatty-acid-binding pocket within the interior of the protein and competitively inhibits the binding of endogenous fatty acids. BMS-309403 sodium improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells .
|
-
-
- HY-12203
-
|
|
Autophagy
Apoptosis
|
Cancer
|
|
PFK-158 is a potent and selective PFKFB3 inhibitor with an IC50 value 137 nM. PFK-158 reduces glucose uptake, ATP production, lactate release, and induces apoptosis and autophagy in cancer cells. PFK-158 has broad anti-tumor activity. PFK-158 can also enhance Colistin's resistance to bacteria .
|
-
-
- HY-18686
-
|
|
Phosphatase
Akt
|
Metabolic Disease
|
|
AS1949490 is a potent, orally active, selective SHIP2 phosphatase inhibitor with IC50 values of 0.34, 0.62, 13, >50, >50, and >50 µM for Mouse SHIP2, Human SHIP2, Human SHIP1, Human PTEN, Human synaptojanin, and Human myotubularin, respectively. AS1949490 increases the phosphorylation of Akt, glucose consumption and glucose uptake. AS1949490 activates intracellular insulin signalling pathways. AS1949490 can be used for research of diabetes .
|
-
-
- HY-18728
-
|
|
GLUT
Autophagy
|
Cancer
|
|
STF-31 is a selective inhibitor of glucose transporter 1 (GLUT1), with an IC50 of 1 μM. STF-31 is also a NAMPT inhibitor. STF-31 inhibits glucose uptake in renal cell carcinoma (RCC) 4 cells .
|
-
-
- HY-N0466
-
|
|
Glycosidase
HMG-CoA Reductase (HMGCR)
Fatty Acid Synthase (FASN)
LDLR
|
Others
|
|
Rebaudioside A is an orally effective steviol glycoside with high sweetness. Rebaudioside A acts as an inhibitor of α-glucosidase with an IC50 value of 35.01 μg/mL. Rebaudioside A increases the ATP/ADP ratio in β cells in a glucose-dependent manner, thereby inhibiting KATP channels, leading to membrane depolarization, calcium influx, and ultimately stimulating insulin secretion. Rebaudioside A activates the SREBP signaling pathway by inhibiting HMGCR, the rate-limiting enzyme in cholesterol synthesis, resulting in increased expression of LDLR on the cell surface, thus promoting the uptake of LDL-C in the blood. Rebaudioside A can be used for studies on blood glucose and lipid regulation as well as anti-obesity .
|
-
-
- HY-W134327A
-
|
Diethylaminoethyl dextran (MW 500000)
|
Biochemical Assay Reagents
|
Others
|
|
DEAE-Dextran (MW 500000) is a complex carbohydrate polymer consisting of glucose molecules linked by glycosidic bonds and modified with diethylaminoethyl (DEAE) groups. DEAE-Dextran is a cationic molecule that can be used as a transfection reagent to deliver nucleic acids such as DNA or RNA into cells. Its positive charge interacts with negatively charged cell membranes, facilitating the uptake of nucleic acids. DEAE-Dextran can also be used as an ion-exchange chromatography resin, allowing the separation and purification of biomolecules based on their charge.
|
-
-
- HY-148983
-
|
|
Monoamine Oxidase
Bacterial
GLUT
|
Infection
Metabolic Disease
Inflammation/Immunology
|
|
Hydroxylamine (50% w/w in water) is an inorganic highly reactive compound and antibacterial agent. Hydroxylamine (50% w/w in water) acutely activates the transport activity of GLUT1, inhibits Monoamine oxidase activity. Hydroxylamine (50% w/w in water) inhibits nitrite oxidizing bacteria. Hydroxylamine (50% w/w in water) activates glucose uptake. Hydroxylamine (50% w/w in water) can be used in the research of inflammatory diseases and allergies[1][2][3][4] .
|
-
-
- HY-N2486
-
|
|
Fatty Acid Synthase (FASN)
Apoptosis
|
Cancer
|
|
Desoxyrhaponticin is a kind of oral drug that inhibits effective fatty acid synthesis (FASN), and has a fatal effect on cancer cells. Desoxyrhaponticin has the ability to inhibit glucose uptake, improve oral glucose tolerance as a diabetic agent, and possess anti-diabetic effects.
|
-
-
- HY-118567
-
|
BMOV
|
SHP2
Phosphatase
|
Metabolic Disease
|
|
Bis(maltolato)oxovanadium(IV) (BMOV) is a potent, reversible, competitive and orally active pan-PTP (protein tyrosine phosphatases) inhibitor. Bis(maltolato)oxovanadium(IV) inhibits HCPTPA, PTP1B, HPTPβ and SHP2 with IC50s of 126 nM, 109 nM, 26 nM and 201 nM, respectively. Bis(maltolato)oxovanadium(IV) is a potent insulin sensitizer .
|
-
-
- HY-124418
-
SBI-477
1 Publications Verification
|
Fluorescent Dye
Insulin Receptor
LXR
Arrestin
|
Metabolic Disease
|
|
SBI-477 is a chemical probe that stimulates insulin signaling by deactivating the transcription factor MondoA. SBI-477 can lead to reduced expression of the insulin pathway suppressors thioredoxin-interacting protein (TXNIP) and arrestin domain-containing 4 (ARRDC4). SBI-477 coordinately inhibits triacylglyceride (TAG) synthesis and enhances basal glucose uptake in human skeletal myocytes .
|
-
-
- HY-N1511
-
|
|
Sirtuin
Apoptosis
|
Cancer
|
|
Ganoderic acid D, a highly oxygenated tetracyclic triterpenoid, is the major active component of Ganoderma lucidum. Ganoderic acid D upregulates the protein expression of SIRT3 and induces the deacetylated cyclophilin D (CypD) by SIRT3. Ganoderic acid D inhibits the energy reprogramming of colon cancer cells including glucose uptake, lactate production, pyruvate and acetyl-coenzyme production in colon cancer cells . Ganoderic acid D induces HeLa human cervical carcinoma apoptosis .
|
-
-
- HY-158302
-
|
|
GLUT
Apoptosis
|
Cancer
|
|
Glutor is a selective GLUT 1/2/3 inhibitor that can suppress glucose uptake. Glutor can inhibit glycolysis and has anti-tumor activity, inducing cell apoptosis .
|
-
-
- HY-N5083
-
-
-
- HY-101849
-
|
|
GLUT
TNF Receptor
Apoptosis
|
Cardiovascular Disease
Cancer
|
|
Fasentin, a potent glucose uptake inhibitor, inhibits GLUT-1/GLUT-4 transporters. Fasentin preferentially inhibits GLUT4 (IC50=68 μM) over GLUT1. Fasentin is a death receptor stimuli (FAS) sensitizer and sensitizes cells to FAS-induced cell death. Fasentin is also a tumor necrosis factor (TNF) apoptosis-inducing ligand sensitizer. Fasentin blocks glucose uptake in cancer cell lines and has anti-angiogenic activity .
|
-
-
- HY-126411
-
|
|
Lipase
ATP Synthase
|
Others
|
|
Peonidin-3-O-galactoside chloride is an anthocyanin with antioxidant properties and blood-brain barrier permeability. Peonidin-3-O-galactoside chloride inhibits pancreatic lipase, with an IC50 value of 23.2 μg/mL against porcine pancreatic lipase. Peonidin-3-O-galactoside chloride mediates neuroprotection, regulates glucose metabolism, protects cells from high glucose-induced damage, promotes glucose uptake and increases ATP production. Peonidin-3-O-galactoside (chloride) can be used in the research of obesity and neurodegenerative diseases .
|
-
-
- HY-19843
-
|
|
Glucokinase
|
Metabolic Disease
|
|
MK-0941 is a selective, orally active, and allosteric glucokinase activator with EC50s of 240 and 65 nM for recombinant human glucokinase in the presence of 2.5 and 10 mM glucose, respectively. MK-0941 activates hexokinase subtype IV. MK-0941 can increase insulin secretion and glucose uptake. MK-0941 can be studied in research for type 2 diabetes .
|
-
-
- HY-N6258
-
Kahweol
1 Publications Verification
|
AMPK
Apoptosis
|
Metabolic Disease
Cancer
|
|
Kahweol is one of the consituents of the coffee from Coffea Arabica with anti-inflammatory anti-angiogenic, and anti-cancerous activities. Kahweol inhibits adipogenesis and increase glucose uptake by AMP-activated protein kinase (AMPK) activation. Kahweol induces apoptosis.
|
-
-
- HY-124113
-
|
4′‐BR
|
Sirtuin
Apoptosis
Caspase
Lactate Dehydrogenase
GLUT
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
4'-Bromo-resveratrol (4′‐BR) is a dual SIRT1/SIRT3 inhibitor with an IC50 of 0.2 mM for both targets. 4'-Bromo-resveratrol induces caspase-dependent apoptosis, induces G0/G1 cell cycle arrest, and inhiibits proliferation. 4'-Bromo-resveratrol reduces lactate production, glucose uptake, and NAD +/NADH ratio, and downregulates lactate dehydrogenase A and glucose transporter 1 (GLUT1). 4'-Bromo-resveratrol can be used for the research of melanoma .
|
-
-
- HY-N2040
-
|
|
Bacterial
Interleukin Related
|
Infection
Inflammation/Immunology
Cancer
|
|
(20R)-Protopanaxadiol is a metabolite of ginsenosides. (20R)-Protopanaxadiol has anti-inflammatory and antibacterial activities, but shows no significant cytotoxicity against tumor cell lines. In addition, (20R)-Protopanaxadiol can inhibit the uptake of 2-deoxy-D-glucose (2-DG) .
|
-
-
- HY-N0642
-
|
|
Drug Derivative
Calcium Channel
|
Metabolic Disease
|
|
α-L-Rhamnose monohydrate is a neutral sugar present in plants, animals, viruses and bacteria. α-L-Rhamnose monohydrate is a ligand for α-L-rhamnose-recognizing lectin sites, trigger intracellular signaling pathways. α-L-Rhamnose monohydrate induces rhaE and rhaA expression as a specific carbon source in Aspergillus nidulans, while glucose inhibits its cellular uptake. α-L-Rhamnose monohydrate induces rapid and transient increases in intracellular free Ca 2+ concentration in normal human dermal fibroblasts .
|
-
-
- HY-113870
-
|
|
Fluorescent Dye
|
Others
|
|
6-NBDG is a fluorescent glucose analogue, it can be used for fluorescence imaging and monitoring glucose transport and uptake. 6-NBDG can be used as a fluorescent probe for detecting macrophage-rich atherosclerotic plaques .
|
-
-
- HY-N4095
-
|
|
Aryl Hydrocarbon Receptor
Glycosidase
Reactive Oxygen Species (ROS)
GLUT
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Brevifolincarboxylic acid is a phenolic compound. Brevifolincarboxylic acid can be isolated from Duchesnea chrysantha. Brevifolincarboxylic acid inhibits α-glucosidase with an IC50 value of 323.46 μM. Brevifolincarboxylic acid has an inhibitory effect on the aryl hydrocarbon receptor (AhR). Brevifolincarbacid scavenges ROS. Brevifolincarbacid restores the glucose uptake activity of myotubes. Brevifolincarboxylic acid has antitumor activity against lung and gastric cancer. Brevifolincarbacid can be used in the study of diabetes and inflammatory diseases .
|
-
-
- HY-W176629
-
-
-
- HY-N8438
-
|
Methyl lignocerate; Tetracosanoic Acid Methyl Ester
|
Others
|
Metabolic Disease
|
|
Methyl tetracosanoate (Methyl lignocerate) is a fatty acid methyl ester with anti-diabetic activity .
|
-
-
- HY-N2209
-
|
|
PPAR
|
Metabolic Disease
|
|
Angeloylgomisin H, as a major lignin extract of Schisandra rubriflora, has the potential to improve insulin-stimulated glucose uptake by activating PPAR-γ .
|
-
-
- HY-B1608
-
|
|
|
Cardiovascular Disease
Metabolic Disease
|
|
Chromium chloride is a trivalent chromium compound and an essential trace mineral. Chromium chloride enhances insulin-stimulated GLUT4 translocation and glucose uptake in skeletal muscle. Chromium chloride regulates glucose and lipid metabolism, inhibits TNF-α secretion and oxidative stress in monocytes treated with high glucose or H2O2, and reverses hydrogen peroxide-induced cell growth inhibition. Chromium chloride reduces coronary and aortic lipid deposition and serum cholesterol levels in hypercholesterolemic rabbits. Chromium chloride can be used in research related to diabetes and cardiac atherosclerosis .
|
-
-
- HY-N7676
-
Marein
3 Publications Verification
|
AMPK
HDAC
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
|
|
Marein has the neuroprotective effect due to a reduction of damage to mitochondria function and activation of the AMPK signal pathway. Marein improves insulin resistance induced by high glucose in HepG2 cells through CaMKK/AMPK/GLUT1 to promote glucose uptake, through IRS/Akt/GSK-3β to increase glycogen synthesis, and through Akt/FoxO1 to decrease gluconeogenesis. Marein is a HDAC inhibitor with an IC50 of 100 μM. Marein has beneficial antioxidative, antihypertensive, antihyperlipidemic and antidiabetic effects .
|
-
-
- HY-158302A
-
|
|
GLUT
Apoptosis
|
Cancer
|
|
(R)-Glutor is the R-enantiomer of Glutor (HY-158302). Glutor is a selective GLUT 1/2/3 inhibitor that can suppress glucose uptake. Glutor can inhibit glycolysis and has anti-tumor activity, inducing cell apoptosis .
|
-
-
- HY-103721
-
|
|
Sirtuin
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
SIRT6-IN-2 (Compound 5) is a selective and competitive SIRT6 inhibitor (IC50: 34 μM). SIRT6-IN-2 increases acetylation of H3K9 and increases glucose uptake in cultured cells. SIRT6-IN-2 also reduces T cell proliferation. SIRT6-IN-2 has immunosuppressive and chemosensitizing effects .
|
-
-
- HY-N7912
-
|
(2S)-Pterosin A
|
AMPK
PEPCK
GSK-3
GLUT
Akt
p38 MAPK
Reactive Oxygen Species (ROS)
|
Metabolic Disease
|
|
Pterosin A ((2S)-Pterosin A) is a sesquiterpene compound. Pterosin A is an orally active AMPK activator with anti-diabetic effect. Pterosin A can promote glucose uptake, increase serum insulin, and improve hyperglycemia and glucose intolerance. Pterosin A can prevent insulin-secreting cells death and reduce ROS production. Pterosin A can be used for the research of metabolic disease, such as diabetes .
|
-
-
- HY-125062
-
|
Glucosilsteviol
|
GLUT
|
Metabolic Disease
|
|
Steviolmonoside (Glucosilsteviol) is a structural analogue of steviol. Steviolmonoside decreases glucose production and inhibits oxygen uptake in rat renal cortical tubules .
|
-
-
- HY-N2486R
-
|
|
Reference Standards
Fatty Acid Synthase (FASN)
Apoptosis
|
Cancer
|
|
Desoxyrhaponticin (Standard) is the analytical standard of Desoxyrhaponticin. This product is intended for research and analytical applications. Desoxyrhaponticin is a kind of oral drug that inhibits effective fatty acid synthesis (FASN), and has a fatal effect on cancer cells. Desoxyrhaponticin has the ability to inhibit glucose uptake, improve oral glucose tolerance as a diabetic agent, and possess anti-diabetic effects .
|
-
-
- HY-P1473
-
|
Amylin (8-37) (mouse, rat)
|
Amylin Receptor
|
Metabolic Disease
|
|
Amylin (8-37), rat is a truncated analog of native Amylin that selectively inhibits insulin-related glucose uptake and glycogen deposition in muscle tissue. Amylin (8-37), rat is a weak amylin receptor (AMY) antagonist.
|
-
-
- HY-B1080A
-
|
|
Influenza Virus
Akt
|
Infection
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Tilorone is an orally active antiviral agent and interferon inducer that also has potential antineoplastic, immunomodulatory, and metabolic modulating effects. Tilorone induces an abnormally delayed interferon response and primarily stimulates interferon production in lymphoid tissue. Thus, Tilorone exerts antiviral effects and can be used as a chemotherapeutic agent. Tilorone has the potential to inhibit type 2 diabetes by increasing glucose uptake in vivo and in skeletal muscle cells by enhancing Akt2/AS160 signaling and glucose transporter levels .
|
-
-
- HY-123194
-
|
|
Histone Demethylase
Sirtuin
|
Metabolic Disease
|
|
SIRT2/6-IN-1 (Compound 5) is a SIRT6/SIRT2 inhibitor, with IC50s of 106 μM and 114 μM. SIRT2/6-IN-1 increases H3K9 acetylation, increases glucose uptake and reduces TNF-α secretion in cells .
|
-
-
- HY-N1185
-
|
|
Others
|
Metabolic Disease
|
|
Tagitinin A is a sesquiterpene with anti-hyperglycemic activity. Tagitinin A significantly inhibits glucose uptake in differentiated 3T3-L1 adipocytes .
|
-
-
- HY-N3426
-
|
|
NO Synthase
Akt
AMPK
|
Metabolic Disease
|
|
Kazinol B, a prenylated flavan with a dimethyl pyrane ring, is an inhibitor of nitric oxide (NO) production. Kazinol B improves insulin sensitivity by enhancing glucose uptake via the insulin-Akt signaling pathway and AMPK activation. Kazinol B has the potential for diabetes mellitus research .
|
-
-
- HY-148940
-
-
-
- HY-D2433
-
|
|
Fluorescent Dye
|
Others
|
|
Glucose-PEG2000-Cy3 is a Cy3 (HY-D0822) labeled Glucose-PEG conjugate. The Cy3 fluorophore is commonly used in applications such as immunolabeling, nucleic acid labeling, fluorescence microscopy, and flow cytometry. Cy3 has an emission maximum around 562-570 nm. Glucose-PEG improves drug cellular uptake and reduces endosomal degradation, and can be used in drug delivery .
|
-
-
- HY-164368
-
|
|
Phosphodiesterase (PDE)
Insulin Receptor
|
Metabolic Disease
|
|
GLUT4 activator 2 (C59) is an insulin sensitizer, which can be used for research of diabetic diseases. GLUT4 activator 2 improves glucose uptake and insulin sensitivity in rodents. GLUT4 activator 2 interacts with Unc119 and Unc119B resulting in increased insulin sensitivity and GLUT4 translocation .
|
-
-
- HY-N7605
-
|
|
Others
|
Metabolic Disease
|
|
11-epi-mogroside V is a mogroside in the fruit of Siraitia grosvenori. 11-epi-mogroside V exhibits considerable bioactivity in promoting glucose uptake in human HepG2 cells in vitro .
|
-
-
- HY-142088
-
|
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Beauverolide Ka, a cyclotetradepsipeptide, is a metabolite of Beauveria bassiana fungus. Beauverolide Ka stimulates glucose uptake in cultured rat L6 myoblasts at 50 μM. Beauverolide Ka exhibits protecting effects on HEI-OC1 cells at 10 μM and shows dose-dependent activity in both L6 myoblasts and myotubes .
|
-
-
- HY-130319A
-
|
|
PPAR
|
Cardiovascular Disease
Metabolic Disease
|
|
9-HEPE, a oxidation product of Eicosapentaenoic acid, is a racemic mixture of 9(R)-HEPE and 9(S)-HEPE. 9-HEPE induces fatty acid oxidation, adipogenesis, and glucose uptake via activation of PPARs in vivo .
|
-
-
- HY-P10230
-
|
|
Bacterial
|
Infection
|
|
Sublancin is an antimicrobial peptide, which inhibits DNA replication, transcription and translation, without affecting membrane integrity. Sublancin suppresses glucose uptake for the competition of phosphotransferase system (PTS). Sublancin inhibits B. subtilis strain 168 ΔSPβ with MIC of 0.312 μM .
|
-
-
- HY-115461
-
|
|
Insulin Receptor
|
Metabolic Disease
|
|
MID-1 is a disruptor of MG53-IRS-1 (Mitsugumin 53-insulin receptor substrate-1) interaction. MID-1 disrupts molecular association of MG53 with IRS-1 and abolishes MG53-induced IRS-1 ubiquitination and degradation in skeletal muscle, leading to elevated IRS-1 expression level and increased insulin signaling and glucose uptake .
|
-
- HY-153018
-
|
|
Phosphatase
|
Metabolic Disease
|
|
PTP1B-IN-22, a ZINC02765569 derivative, is a potent protein tyrosine phosphatase 1B (PTP1B) inhibitor. PTP1B-IN-22 has PTP1B inhibition and glucose uptake in skeletal muscle L6 myotubes .
|
-
- HY-N0457R
-
|
Cichoric acid (Standard); Dicaffeoyltartaric acid (Standard)
|
Reference Standards
Reactive Oxygen Species (ROS)
Apoptosis
|
Metabolic Disease
Inflammation/Immunology
|
|
Chicoric acid (Standard) is the analytical standard of Chicoric acid. This product is intended for research and analytical applications. Chicoric acid (Cichoric acid), an orally active dicaffeyltartaric acid, induces reactive oxygen species (ROS) generation. Chicoric acid inhibits cell viability and induces mitochondria-dependent apoptosis in 3T3-L1 preadipocytes through ROS-mediated PI3K/Akt and MAPK signaling pathways. Chicoric acid increases glucose uptake, improves insulin resistance, and attenuates glucosamine-induced inflammation. Chicoric acid has antidiabetic properties and antioxidant, anti-inflammatory effects .
|
-
- HY-153612
-
|
|
GLUT
Parasite
|
Infection
Inflammation/Immunology
|
|
MMV009085 is a potent PfHT1 (Plasmodium falciparum hexose transporter)-specific inhibitor and a potential anti-malarial agent . MMV009085 is also a human glucose transporter inhibitor, it has high potency in inhibiting both glucose uptake (IC50: 2.6 μM in glucose uptake assay) and growth of the parasites (EC50: 1.23±0.04 μM against 3D7) .
|
-
- HY-177297
-
|
NVP-LCZ960
|
Glucokinase
|
Metabolic Disease
|
|
LCZ960 is an orally active glucokinase (GK) activator. LCZ960 stimulates GK activity in hepatocytes in vitro and stimulates glucose uptake in vivo through hepatic GK activation. LCZ960 lowers blood glucose in mice with diet-induced obesity (DIO). LCZ960 maintains normoglycemia and improves glucose tolerance in DIO mice and rats. LCZ960 stimulates glycogen synthase flux and increases hepatic glycogen turnover in rats. LCZ960 induces increased hepatic glycogen recycling. LCZ960 can be used to study high-fat diet-induced obesity and type 2 diabetes .
|
-
- HY-136855
-
|
|
Sirtuin
AMPK
PGC-1α
Apoptosis
Reactive Oxygen Species (ROS)
|
Metabolic Disease
|
|
MitoPBN is a AMPK/SIRT3/PGC-1α axis modulator, reactive oxygen species scavenger and mitochondrial function enhancer. MitoPBN increases the phosphorylation level of AMPK, restores SIRT3 expression and reverses the down-regulation of PGC-1α, thereby promoting mitochondrial biogenesis. MitoPBN regulates glucose metabolism, reduces blood glucose by inhibiting hepatic gluconeogenesis and increasing hepatic glucose uptake, while scavenging mitochondrial superoxide anion/hydrogen peroxide, maintaining membrane potential and increasing ATP production. MitoPBN also reduces cell apoptosis, improves sperm motility, survival rate and membrane integrity, but may induce reductive stress in cryopreserved sperm at high concentrations. MitoPBN is widely applicable to research related to diabetes and type 2 diabetes .
|
-
- HY-N0466R
-
|
|
Reference Standards
Glycosidase
HMG-CoA Reductase (HMGCR)
Fatty Acid Synthase (FASN)
LDLR
|
Others
|
|
Rebaudioside A (Standard) is the analytical standard of Rebaudioside A. This product is intended for research and analytical applications. Rebaudioside A is an orally effective steviol glycoside with high sweetness. Rebaudioside A acts as an inhibitor of α-glucosidase with an IC50 value of 35.01 μg/mL. Rebaudioside A increases the ATP/ADP ratio in β cells in a glucose-dependent manner, thereby inhibiting KATP channels, leading to membrane depolarization, calcium influx, and ultimately stimulating insulin secretion. Rebaudioside A activates the SREBP signaling pathway by inhibiting HMGCR, the rate-limiting enzyme in cholesterol synthesis, resulting in increased expression of LDLR on the cell surface, thus promoting the uptake of LDL-C in the blood. Rebaudioside A can be used for studies on blood glucose and lipid regulation as well as anti-obesity.
|
-
- HY-N8490
-
|
|
Others
|
Metabolic Disease
|
|
Eicosyl ferulate, a phenolic compound, is isolated from the fresh root and stem of Aristolochia kankauensis. Eicosyl ferulate exhibits glucose uptake stimulatory activity .
|
-
- HY-W411439
-
|
|
GLUT
|
Metabolic Disease
|
|
1-O-p-Coumaroyl-β-D-glucose can promote glucose uptake in HuH7 cells, and be be extracted from Luffa cylindrica (L.) Roem (sponge gourds) .
|
-
- HY-167857
-
|
|
GLUT
|
Cancer
|
|
(Rac)-Glutipyran is a broad-spectrum GLUT inhibitor that targets both GLUT1 and GLUT3. (Rac)-Glutipyran inhibits glucose uptake and suppresses the growth of multiple cancer cells, significantly inhibiting PANC-1 cell growth (IC50=1.8 μM) and glucose uptake (IC50=0.13 μM) .
|
-
- HY-146036
-
|
|
Endogenous Metabolite
|
Metabolic Disease
|
|
NADH-IN-1 has NADH:ubiquinone oxidoreductase inhibitory activity with an IC50 value of 27 μM. NADH-IN-1 can effectively stimulate glucose uptake in vitro. NADH-IN-1 is readily metabolised by the liver. NADH-IN-1 can be used for researching diabetes .
|
-
- HY-139172
-
|
|
PPAR
|
Metabolic Disease
|
|
MD001 is a PPARα/γ dual agonist and can increase the transcriptional activity of PPARα and PPARγ. MD001 enhances the expression of genes related to β-oxidation and fatty acid and glucose uptake .
|
-
- HY-163294
-
|
|
PPAR
|
Metabolic Disease
|
|
PPARγ agonist 10 (compound 33g) is a PPARγ agonist, and stimulats the insulin secretion, glucose uptake and insulin Sensitivity in βTC6 Cells .
|
-
- HY-N16431
-
|
|
AMPK
Nuclear Factor of activated T Cells (NFAT)
Interleukin Related
Endogenous Metabolite
|
Metabolic Disease
Inflammation/Immunology
|
|
NFAT-133 is an aromatic polyketide with immunosuppressive and antidiabetic activity. NFAT-133 activates the AMPK pathway, promoting glucose uptake in L6 muscle fibers, thereby resisting diabetes. NFAT-133 inhibits the transcriptional activity of activated T-cell nuclear factor (NFAT), thereby suppressing the expression of IL-2 and the proliferation of T cells, demonstrating an immunosuppressive effect. NFAT-133 does not exhibit antibacterial activity or cytotoxicity, but it can weaken the production of NO in RAW264.7 cells induced by Lipopolysaccharide (LPS) (HY-D1056) .
|
-
- HY-N5083R
-
-
- HY-101903R
-
|
|
Reference Standards
FABP
|
Cardiovascular Disease
Metabolic Disease
|
|
BMS-309403 (Standard) is the analytical standard of BMS-309403. This product is intended for research and analytical applications. BMS-309403 is a potent, orally active and selective adipocyte fatty acid binding protein (also known as FABP4, aP2) inhibitor with Kis of <2, 250, and 350 nM for FABP4, FABP3, and FABP5, respectively. BMS-309403 interacts with the fatty-acid-binding pocket within the interior of the protein and competitively inhibits the binding of endogenous fatty acids. BMS-309403 improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells .
|
-
- HY-101903AR
-
|
|
Reference Standards
FABP
|
Cardiovascular Disease
Metabolic Disease
|
|
BMS-309403 (sodium) (Standard) is the analytical standard of BMS-309403 (sodium). This product is intended for research and analytical applications. BMS-309403 sodium is a potent, orally active, and selective adipocyte fatty acid binding protein (also known as FABP4, aP2) inhibitor, with Kis of <2, 250, and 350 nM for FABP4, FABP3, and FABP5, respectively. BMS-309403 sodium interacts with the fatty-acid-binding pocket within the interior of the protein and competitively inhibits the binding of endogenous fatty acids. BMS-309403 sodium improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells .
|
-
- HY-156690
-
|
|
Others
|
Metabolic Disease
|
|
2-Quinizarincarboxylic acid (Compound 15) is a glucose uptake inhibitor, with the inhibitory rate of 24.9% at 50 μM .
|
-
- HY-124417
-
|
|
GLUT
|
Metabolic Disease
|
|
SBI-477 (compound 41) analog inhibits intracellular lipid accumulation, increase celluar glucose uptake .
|
-
- HY-178167
-
|
|
SGLT
|
Metabolic Disease
|
|
SGLT2-IN-3 is a sodium-glucose co-transporter 2 (SGLT2) inhibitor. SGLT2-IN-3 can inhibit glucose uptake. SGLT2-IN-3 can be used for the research of metabolic disease, such as diabetes .
|
-
- HY-138842
-
|
|
Insulin Receptor
Akt
ERK
|
Metabolic Disease
|
|
DDN is a selective insulin receptor (Insulin Receptor) activator, an insulin sensitizer, and a glucose-lowering insulin mimetic with oral bioavailability. DDN can directly bind to the receptor kinase domain and induce Akt and ERK phosphorylation, and it can also enhance insulin's effect on glucose uptake. DDN significantly reduces blood glucose levels in wild-type and diabetic ob/ob and db/db mice .
|
-
- HY-167857S
-
|
|
Isotope-Labeled Compounds
GLUT
|
Cancer
|
|
Glutathione Disulfide- 13C4, 15N2 is the 13C- and 15N-labeled (Rac)-Glutipyran (HY-167857). (Rac)-Glutipyran is a broad-spectrum GLUT inhibitor that targets both GLUT1 and GLUT3. (Rac)-Glutipyran inhibits glucose uptake and suppresses the growth of multiple cancer cells, significantly inhibiting PANC-1 cell growth (IC50=1.8 μM) and glucose uptake (IC50=0.13 μM) .
|
-
- HY-163279
-
|
|
Glycosidase
|
Others
|
|
Fluopipamine is an antagonist for Cellulose Synthase 1 (CESA1) with an IC50 of 0.78 μM. Fluopipamine leads a decrease in glucose uptake into cellulose and hyperaccumulation of CESAs at the PM in etiolated Arabidopsis seedlings .
|
-
- HY-155961
-
-
- HY-101849R
-
|
|
Reference Standards
GLUT
TNF Receptor
Apoptosis
|
Cardiovascular Disease
Cancer
|
|
Fasentin (Standard) is the analytical standard of Fasentin. This product is intended for research and analytical applications. Fasentin, a potent glucose uptake inhibitor, inhibits GLUT-1/GLUT-4 transporters. Fasentin preferentially inhibits GLUT4 (IC50=68 μM) over GLUT1. Fasentin is a death receptor stimuli (FAS) sensitizer and sensitizes cells to FAS-induced cell death. Fasentin is also a tumor necrosis factor (TNF) apoptosis-inducing ligand sensitizer. Fasentin blocks glucose uptake in cancer cell lines and has anti-angiogenic activity .
|
-
- HY-123765
-
|
|
Acyltransferase
|
Metabolic Disease
|
|
JTT-553 is a DGAT1 inhibitor (IC50: 2.38 nM). JTT-553 reduces plasma concentrations of glucose, insulin, non-esterified fatty acids (NEFA), total cholesterol (TC), and hepatic triglycerides (TG). JTT-553 improves insulin-dependent glucose uptake and glucose intolerance in adipose tissue of DIO mice. JTT-553 reduces TNF-α mRNA levels and increases GLUT4 mRNA levels in adipose tissue of KK-Ay mice. JTT-553 improves adipose tissue insulin resistance and systemic glucose metabolism by reducing body weight. JTT-553 can be used in the study of obesity and type 2 diabetes mellitus (T2DM) .
|
-
- HY-149727
-
|
|
Adrenergic Receptor
|
Metabolic Disease
|
|
β2AR agonist 2(compound 8a) is a β2 -Adrenergic receptor (β2AR) agonist. β2AR agonist 2 is a saturated nitrogen ring compound containing 4- to 7-membered heterocycle. β2AR agonist 2 has a chiral structure (the -R form) by carrying carbon containing the essential hydroxyl, thereby enhancing cellular glucose uptake (GU) activity and significantly stimulating glucose uptake by skeletal muscle cells. β2AR agonist 2 can be used in the study of Type 2 Diabetes (T2D) .
|
-
- HY-168706
-
|
|
Phosphatase
|
Metabolic Disease
|
|
LXQ-87 is an oral noncompetitive inhibitor of PTP1B with an IC50 of 1.061 μM, showing hypoglycemic activity. LXQ-87 alleviates insulin resistance and promotes cellular glucose uptake, making it useful for research on type 2 diabetes .
|
-
- HY-174700
-
|
|
mRNA
|
Cancer
|
|
Human FGF21 mRNA encodes the human fibroblast growth factor 21 (FGF21) protein, a member of the fibroblast growth factor (FGF) family. FGF21 is a secreted endocrine factor that functions as a major metabolic regulator. It stimulates the uptake of glucose in adipose tissue.
|
-
- HY-169404
-
|
|
PPAR
|
Metabolic Disease
|
|
PPARγ agonist 15 (Compound 7c) is an agonist for PPARγ. PPARγ agonist 15 inhibits the expression of alpha-amylase (HPA) and alpha-glucosidase (HLAG) with IC50 of 28.35 µM and 26.21 µM. PPARγ agonist 15 enhances glucose uptake in the L6 myotube cell. PPARγ agonist 15 improves glucose homeostasis, insulin sensitivity, and lipid metabolism in rat Streptozotocin (HY-13753)-induced diabetes model .
|
-
- HY-118236
-
|
(S)-KIN-193
|
PI3K
|
Cardiovascular Disease
|
|
(S)-AZD6482 ((S)-KIN-193) is a highly effective and selective ATP-competitive inhibitor of PI3Kβ, exhibiting an IC(50) of 0.01 μM, and it can reduce insulin-induced glucose uptake by human adipocytes in vitro with an IC(50) of 4.4 μM.
|
-
- HY-N6258R
-
|
|
Reference Standards
AMPK
Apoptosis
|
Metabolic Disease
|
|
Kahweol (Standard) is the analytical standard of Kahweol. This product is intended for research and analytical applications. Kahweol is one of the consituents of the coffee from Coffea Arabica with anti-inflammatory anti-angiogenic, and anti-cancerous activities. Kahweol inhibits adipogenesis and increase glucose uptake by AMP-activated protein kinase (AMPK) activation. Kahweol induces apoptosis.
|
-
- HY-171793
-
|
|
PPAR
|
Metabolic Disease
|
|
DN-108, a thiazolidinedione derivative, is an orally active peroxisome proliferator-activated receptor γ (PPARγ) agonist with antidiabetic effects. DN-108 improves hyperglycemia, hypertriglyceridemia and hyperinsulinemia in diabetic mouse models. DN-108 enhances tissue glucose uptake (e.g., increasing 2-deoxyglucose uptake in L6 muscle cells) and inhibits fatty acid synthase activity. DN-108 is promising for research of type 2 diabetes .
|
-
- HY-174687
-
|
|
mRNA
|
Cancer
|
|
Human FGFR4 mRNA encodes the human fibroblast growth factor receptor 4 (FGFR4) protein, a tyrosine kinase and cell surface receptor for fibroblast growth factors. FGFR4 is involved in the regulation of several pathways, including cell proliferation, cell differentiation, cell migration, lipid metabolism, bile acid biosynthesis, vitamin D metabolism, glucose uptake, and phosphate homeostasis.
|
-
- HY-143260
-
|
|
GSK-3
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
GSK-3β inhibitor 6 is a potent GSK-3β inhibitor with an IC50 value of 24.4 μM. GSK-3β inhibitor 6 shows high hepatocyte glucose uptake (38%). GSK-3β inhibitor 6 can be used in the research of numerous diseases like diabetes, inflammation, cancer, Alzheimer's disease, and bipolar disorder .
|
-
- HY-13991A
-
|
|
Ras
|
Metabolic Disease
Cancer
|
|
(S)-CCG-1423 is an inhibitor of Rho signaling that blocks the nuclear import of MRTF-A. (S)-CCG-1423 reduces the nuclear accumulation of MRTF-A and improves glucose uptake and tolerance in insulin-resistance mice in vivo. (S)-CCG-1423 exhibits higher inhibition activity than the SR- and the R-isomers of CCG-1423 (HY-13991). (S)-CCG-1423 can be used for the research of cancer and diabetes .
|
-
- HY-132898
-
|
|
PI3K
|
Others
|
|
PI3K-IN-23 is an (E)-9-oxooctadec-10-en-12-ynoic acid analogue to promote glucose uptake with an EC50 value of 7.00 μM. PI3K-IN-23 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-168495
-
|
|
Amylases
Glycosidase
|
Metabolic Disease
|
|
α-Amylase-IN-12 (Compound 5e) is an α-amylase inhibitor (IC50: 0.15 mM) with a mixed inhibition. α-Amylase-IN-12 has an IC50 of 9.40 mM against α-glucosidase. α-Amylase-IN-12 promotes glucose uptake in yeast cells and exhibits significant antiglycation activity at high concentrations. α-Amylase-IN-12 can be used for the research of diabetes .
|
-
- HY-176051
-
|
RgE
|
GLUT
|
Cancer
|
|
Rapaglutin E (RgE) is a glucose transporter (GLUT) inhibitor. Rapaglutin E exhibits dose-dependent inhibition of [ 3H]-2DG uptake in A549, Jurkat T, PANC10.05, and RBC, with IC50 values 8.9 nM, 3.1 nM, 35.5 nM, 74.2 nM. Rapaglutin E inhibits cell proliferation in A549, PANC10.05, HeLa, Jurkat T, and HEK293T cells .
|
-
- HY-D3199
-
|
|
Fluorescent Dye
GLUT
|
Metabolic Disease
|
|
NIR-fluorescent glucose is a functional glucose-based fluorescent imaging agent. Conjugated with the nitrobenzoselenadiazole-based SCOTfluor (compound 9), NIR-fluorescent glucose acts as a substrate for GLUT4 and GLUT2 transporters. NIR-fluorescent glucose enables the visualization of glucose uptake in live cells and in vivo .
|
-
- HY-103721R
-
|
|
Sirtuin
Reference Standards
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
SIRT6-IN-2 (Standard) is the analytical standard of SIRT6-IN-2 (HY-103721). This product is intended for research and analytical applications. SIRT6-IN-2 (Compound 5) is a selective and competitive SIRT6 inhibitor (IC50: 34 μM). SIRT6-IN-2 increases acetylation of H3K9 and increases glucose uptake in cultured cells. SIRT6-IN-2 also reduces T cell proliferation. SIRT6-IN-2 has immunosuppressive and chemosensitizing effects .
|
-
- HY-181233
-
|
|
PPAR
|
Metabolic Disease
|
|
PPARγ agonist-22 is a PPARγ agonist. PPARγ agonist-22 promotes cellular glucose uptake. PPARγ agonist-22 reduces lipid accumulation in adipocytes. PPARγ agonist-22 can be used in the research of type 2 diabetes .
|
-
- HY-17604
-
|
EGT1442; EGT0001442; THR-1442
|
SGLT
|
Cardiovascular Disease
Metabolic Disease
|
|
Bexagliflozin (EGT1442) is an orally active and selective SGLT2 inhibitor with IC50 values of 0.002 μM and 5.6 μM for SGLT2 and SGLT1, respectively. Bexagliflozin selectively inhibits SGLT2-mediated sodium-dependent glucose uptake. Bexagliflozin induces saturable urinary glucose excretion in normal rats and dogs. Bexagliflozin reduces blood glucose and HbA1c levels in db/db mice without affecting body mass or insulin level. Bexagliflozin can be used for the research of type 2 diabetes mellitus, hypertensive stroke .
|
-
- HY-138976
-
-
- HY-167931
-
|
|
Drug Derivative
|
Metabolic Disease
|
|
Cinnamohydrazide, an unsaturated carboxylic acid derivative, serves as a precursor to aspartame through enzyme-mediated amination to phenylalanine. This compound may offer potential benefits in the prevention and treatment of diabetes by facilitating insulin secretion, enhancing pancreatic β-cell function, inhibiting hepatic gluconeogenesis, promoting glucose uptake, amplifying insulin signaling pathways, delaying carbohydrate digestion and glucose absorption, and reducing protein glycation and insulin fibrillation.
|
-
- HY-D3196
-
|
|
Fluorescent Dye
|
Cancer
|
|
AG2 is a glucose uptake tracer and two-photon fluorescent probe. AG2 is taken up by cells via glucose-specific transport systems, rather than passive diffusion; it preferentially accumulates in cancer cells and colon cancer tissues compared with normal cells and tissues; it mainly localizes to mitochondria, with a small amount also distributed in the cytoplasm and cell membrane. AG2 can be used for colon cancer research .
|
-
- HY-182558
-
|
|
Drug Derivative
AMPK
IKK
NF-κB
|
Metabolic Disease
|
|
Nandinine is an orally active derivative of Berberine (HY-N0716). Nandinine enhances AMPK activity, inhibits the activation of IKKβ/NF-κB, and regulates the phosphorylation of IRS-1. Nandinine reverses the abnormal production of adipokines, promotes insulin-mediated glucose uptake, and alleviates insulin resistance. Nandinine improves glucose tolerance and increases the insulin sensitivity index in mice. Nandinine can be used in studies related to insulin resistance .
|
-
- HY-N18033
-
|
|
Insulin Receptor
GLP Receptor
|
Metabolic Disease
|
|
Glyceollin III is a glyceollin found in soybeans. Glyceollin III enhances insulin-stimulated glucose uptake and increases glucagon-like peptide-1 (GLP-1) secretion. Glyceollin III can be used for the research of type 2 diabetes .
|
-
- HY-W207669
-
|
|
Insulin Receptor
|
Metabolic Disease
|
|
Centpiperalone is an orally active hypoglycemic agent. Centpiperalone mainly achieves its hypoglycemic effect by promoting the release of insulin by pancreatic β cells. Centpiperalone can effectively lower blood sugar levels in both normal and diabetic animals. Centpiperalone can be used in research on diabetes .
|
-
- HY-183069
-
|
|
GLUT
PI3K
Akt
Apoptosis
Bcl-2 Family
|
Cancer
|
|
FKL-137 is a GLUT1 and PI3K/AKT signaling pathway inhibitor. FKL-137 binds to GLUT1, reduces glucose uptake and lactate secretion, downregulates glucose metabolism-related proteins, and inhibits erythroleukemia cell proliferation. FKL-137 downregulates PI3K, p-PI3K, AKT, p-AKT levels, disrupts the PI3K/AKT-GLUT1 positive feedback loop, and suppresses erythroleukemia cell proliferation. FKL-137 induces apoptosis via upregulated Bax, Cleaved-PARP and downregulated Bcl-2, PARP. FKL-137 can be used for the research of erythroleukemia .
|
-
- HY-N17773
-
|
|
PPAR
GLUT
TNF Receptor
|
Metabolic Disease
|
|
Hydrangeic acid is an orally effective stilbene-type glycolipid metabolism regulator that lowers blood glucose and lipids. It can be isolated from processed leaves of Hydrangea macrophylla var. thunbergii. Hydrangeic acid is associated with glycolipid metabolism and insulin sensitivity regulation. Hydrangeic acid does not directly activate PPARγ or PPARα, but instead upregulates the mRNA expression of adiponectin, PPARγ2, GLUT4, and fatty acid-binding protein aP2, and downregulates TNF-α mRNA expression, promoting adipogenesis, glucose uptake, and GLUT4 translocation in 3T3-L1 cells. Simultaneously, Hydrangeic acid inhibits inflammatory factor-induced NO production, exerting activity in improving insulin resistance. Hydrangeic acid can be used in research related to type 2 diabetes and does not cause liver weight gain as a side effect.
|
-
- HY-W1126235
-
|
D223
|
Molecular Glues
Ras
PI3K
GLUT
|
Metabolic Disease
|
|
DS02312223 (D223) is a molecular glue that promotes the binding of RAS to PI3Kα, with a Kd of 0.76 μM for p110α. DS02312223 increases the binding affinity between GTP-bound KRAS (KRAS-GMPPNP) and p110α by nearly three orders of magnitude (KD = 0.017 μM). DS02312223 stimulates the translocation of GLUT4 to the plasma membrane. DS02312223 promotes glucose uptake in the absence of insulin. DS02312223 can be used in diabetes research .
|
-
- HY-159944
-
|
|
PPAR
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
|
|
PPARγ agonist 14 (compound 3) is a PPARy agonist (EC50=2.4 μM) with anti-diabetic activity. PPARγ agonist 14 can improve intracellular glucose uptake, promote insulin release, and lower blood sugar. In addition, PPARγ agonist 14 also improves mitochondrial function, reduces oxidative stress, and inhibits inflammatory factors. PPARγ agonist 14 can be used in the study of neurodegenerative diseases, neuroinflammatory diseases, and other diseases .
|
-
- HY-N5123
-
|
|
Endogenous Metabolite
|
Metabolic Disease
|
|
α-L-Rhamnose is a neutral sugar present in plants, animals, viruses and bacteria. α-L-Rhamnose is a ligand for α-L-rhamnose-recognizing lectin sites, trigger intracellular signaling pathways. α-L-Rhamnose induces rhaE and rhaA expression as a specific carbon source in Aspergillus nidulans, while glucose inhibits its cellular uptake. α-L-Rhamnose induces rapid and transient increases in intracellular free Ca 2+ concentration in normal human dermal fibroblasts .
|
-
- HY-143261
-
|
|
GSK-3
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
GSK-3β inhibitor 7 is a GSK-3β inhibitor with an IC50 value of 5.25 μM. GSK-3β inhibitor 7 is inserted into the ATP-binding binding pocket of GSK-3β and forms hydrogen-bond. GSK-3β inhibitor 7 shows high hepatocyte glucose uptake (83.5%), and can be used in the research of numerous diseases like diabetes, inflammation, cancer, Alzheimer's disease, and bipolar disorder .
|
-
- HY-N17326
-
|
|
Acyltransferase
Phosphatase
Interleukin Related
|
Metabolic Disease
Inflammation/Immunology
|
|
Ilekudinol B is an inhibitor of ACAT and PTP1B, with an IC50 of 5.3 μM and a Ki of 11.6 μM against human PTP1B. Ilekudinol B inhibits the classical pathway of the complement system, with an IC50 of 51 μM. Ilekudinol B inhibits TNF-α-induced cellular IL-8 secretion, promotes glucose uptake in skeletal muscle myotubes, and acts as an insulin mimetic and insulin sensitizer. Ilekudinol B can be used in research related to type 2 diabetes, obesity, and inflammatory diseases .
|
-
- HY-DY1019
-
|
|
Fluorescent Dye
|
Others
|
2-NBDG (solution) is a fluorescently-labeled deoxyglucose analog that is used primarily to directly monitor glucose uptake by living cells and tissues. It is also used as a topical contrast reagent for the detection of neoplasia. 2-NBDG can be used in real-time confocal, high-resolution, or wide-field fluorescence microscopy as well as in flow cytometry. The probe can be excited by the Argon laser at 488 nm to give the environment-sensitive fluorescence. It has lower photostability than the rhodamine-based fluorescent probes. Solvent and Concentration: Sterile PBS: 5 mM
|
-
- HY-N1511R
-
|
|
Reference Standards
Sirtuin
Apoptosis
|
Cancer
|
|
Ganoderic acid D (Standard) is the analytical standard of Ganoderic acid D. This product is intended for research and analytical applications. Ganoderic acid D, a highly oxygenated tetracyclic triterpenoid, is the major active component of Ganoderma lucidum. Ganoderic acid D upregulates the protein expression of SIRT3 and induces the deacetylated cyclophilin D (CypD) by SIRT3. Ganoderic acid D inhibits the energy reprogramming of colon cancer cells including glucose uptake, lactate production, pyruvate and acetyl-coenzyme production in colon cancer cells . Ganoderic acid D induces HeLa human cervical carcinoma apoptosis .
|
-
- HY-180805
-
|
|
Hexokinase
Mitophagy
Apoptosis
GLUT
|
Cancer
|
|
HK2-IN-3 (compound 12) is a potent hexokinase 2 (HK2) inhibitor with an IC50 of 56.4 nM. HK2-IN-3 reduces glucose uptake and downregulated GLUT1/GLUT4 in oral squamous cell carcinoma (OSCC). HK2-IN-3 induces mitophagy and apoptosis. HK2-IN-3 suppresses tumor growth and angiogenesis in OSCC xenograft mouse models. HK2-IN-3 can be used for OSCC research .
|
-
- HY-116522
-
-
- HY-176214
-
|
|
PPAR
COX
|
Metabolic Disease
|
|
PPARγ agonist 19 (Compound 5e) is a PPARγ agonist. PPARγ agonist 19 has an IC50 of 11.27 μM against COX-1 and an IC50 of 0.05 μM against COX-1. PPARγ agonist 19 increases glucose uptake in rat hemidiaphragm assay and is superior to pioglitazone (HY-13956). PPARγ agonist 19 alleviates hyperglycemia and insulin resistance in an in vivo model of type 2 diabetes in rats and protects against renal and lipidemia damage caused by metabolic dysfunction .
|
-
- HY-N4095R
-
|
|
Reference Standards
Aryl Hydrocarbon Receptor
Glycosidase
Reactive Oxygen Species (ROS)
GLUT
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Brevifolincarboxylic acid (Standard) is the analytical standard of Brevifolincarboxylic acid (HY-N4095). This product is intended for research and analytical applications. Brevifolincarboxylic acid is a phenolic compound. Brevifolincarboxylic acid can be isolated from Duchesnea chrysantha. Brevifolincarboxylic acid inhibits α-glucosidase with an IC50 value of 323.46 μM. Brevifolincarboxylic acid has an inhibitory effect on the aryl hydrocarbon receptor (AhR). Brevifolincarbacid scavenges ROS. Brevifolincarbacid restores the glucose uptake activity of myotubes. Brevifolincarboxylic acid has antitumor activity against lung and gastric cancer. Brevifolincarbacid can be used in the study of diabetes and inflammatory diseases .
|
-
- HY-173115
-
|
|
COX
Lipoxygenase
Interleukin Related
PPAR
|
Metabolic Disease
Inflammation/Immunology
|
|
15-LOX-IN-2 (Compound 2a) is an orally active COX-2/15-LOX inhibitor and a partial agonist of PPARγ. 15-LOX-IN-2 has anti-inflammatory activity and inhibits the levels of 20-HETE, IL-1β and TNF-α in RAW 264.7 cells treated with LPS (HY-D1056). In addition, 15-LOX-IN-2 has significant glucose uptake capacity in the absence of insulin. 15-LOX-IN-2 can be used for the research of metabolic diseases .
|
-
- HY-N3055
-
|
|
Apoptosis
AMPK
Platelet-activating Factor Receptor (PAFR)
Caspase
|
Neurological Disease
Metabolic Disease
Cancer
|
|
Pinusolide is an AMPK activator and PAF receptor antagonist. Pinusolide activates AMPK, phosphorylates ACC, enhances IRS-1 tyrosine phosphorylation, boosts glucose uptake, and modulates insulin signaling. Pinusolide inhibits caspase-3/7 activation, intracellular calcium elevation, reactive oxygen species overproduction, lipid peroxidation, and tumor cell proliferation. Pinusolide stabilizes superoxide dismutase activity, reduces apoptotic hallmarks, induces mitochondrial pathway apoptosis, and triggers DNA fragmentation. Pinusolide can be used for the research of type 2 diabetes, neurodegenerative diseases, acute lymphoblastic leukemia, acute myeloid leukemia, and Burkitt lymphoma .
|
-
- HY-107207
-
|
Kaempferol 3-O-neohesperidoside
|
Insulin Receptor
PI3K
PKC
|
Metabolic Disease
|
|
Kaempferol 3-neohesperidoside (Kaempferol 3-O-neohesperidoside) is a flavonoid. Kaempferol 3-neohesperidoside mimics insulin action via the PI3K/PKC pathway, significantly promoting glucose uptake and increasing muscle glycogen content in rat soleus muscles. Kaempferol 3-neohesperidoside also exhibits anti-glycation activity. Kaempferol 3-neohesperidoside binds to albumin through hydrogen bonding and hydrophobic interactions, and inhibits the formation of advanced glycation end products. Kaempferol 3-neohesperidoside can be used in studies of diabetes and its related complications .
|
-
- HY-N8540
-
|
|
Phosphoglycerate Kinase (PGK)
Fungal
Apoptosis
|
Infection
Cancer
|
|
Ilicicolin H is a selective and non-ATP-competitive phosphoglycerate kinase 1 (PGK1) (IC50 = 9.02 μM) and mitochondrial cytochrome bc1 reductase (IC50 = 2-3 ng/mL) inhibitor. Ilicicolin H directly binds to PGK1 with KD of 60 μM .Ilicicolin H can inhibit cell proliferation and induce apoptosis. Ilicicolin H can inhibit the lactate production and glucose uptake of hepatocellular carcinoma (HCC) cells. Ilicicolin H has a broad antifungal spectrum including C. albicans, Cryptococcus and A. fumigatus. Ilicicolin H can be used for the researches of cancer and infection, such as hepatocellular carcinoma (HCC) and C. albicans infection .
|
-
- HY-124689
-
|
|
Arp2/3 Complex
|
Metabolic Disease
Cancer
|
|
TR-100 is a small molecule inhibitor of tumor-associated troponin (Tpm). TR-100 affects the interaction of Tpm3.1 with actin filaments by binding to the C-terminal of Tpm3.1, thereby affecting the stability and function of the actin filaments. This mechanism of action allows TR-100 to specifically affect actin filaments in cancer cells without compromising heart muscle function. TR-100 can be used to study the role of Tpm3.1 in cancer cell proliferation and survival and the effects of Tpm3.1 on insulin-stimulated glucose uptake and insulin secretion .
|
-
- HY-180398
-
|
|
PPAR
PGC-1α
|
Metabolic Disease
|
|
PA-082 is a selective PPAR-γ modulator that functions as a partial agonist. PA-082 causes partial recruitment of SRC1, TIF2, SRC3 and full recruitment of PGC1-α to PPAR-γ ligand-binding domain. PA-082 prevents triglyceride accumulation during de novo adipogenesis and antagonizes Rosiglitazone (HY-17386)-induced lipid accumulation. PA-082 potentiates insulin-stimulated glucose uptake in adipocytes and protects against TNFα-induced insulin resistance. PA-082 can be used for the research of type 2 diabetes .
|
-
- HY-N4150
-
|
Quercetagetin-7-O-glucoside
|
Phosphatase
Tau Protein
NF-κB
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
|
|
Quercetagitrin (Quercetagetin-7-O-glucoside) is a natural product that can be isolated from the African marigold (Tagetes erecta). Quercetagitrin has anti-inflammatory activity. Quercetagitrin inhibits Tau accumulation. Quercetagitrin can reverse neuroinflammation and cognitive deficits in P301S-Tau transgenic mouse model through inhibiting NF-κB activation. Quercetagitrin is a dual-target inhibitor of PTPN6 (IC50 = 1 μM) and PTPN9 (IC50 = 1.7 μM). Quercetagitrin enhances glucose uptake by mature C2C12 myoblasts. Quercetagitrin can be studied in research for Alzheimer’s disease and type 2 diabetes .
|
-
- HY-15763
-
Erastin
Maximum Cited Publications
805 Publications Verification
|
VDAC
Ferroptosis
Disulfidptosis
|
Cancer
|
|
Erastin is a ferroptosis inducer. Erastin exhibits the mechanism of ferroptosis induction related to ROS and iron-dependent signaling. Erastin inhibits voltage-dependent anion channels (VDAC2/VDAC3) and accelerates oxidation, leading to the accumulation of endogenous reactive oxygen species. Erastin also disrupts mitochondrial permeability transition pore (mPTP) with anti-tumor activity. Furthermore, Erastin can block the uptake of cystine mediated by SLC7A11 and also spares UMRC6-EV and -C91A cells from disulfidptosis under glucose starvation .
|
-
- HY-158204
-
|
|
Lipoxygenase
Amyloid-β
Reactive Oxygen Species (ROS)
Apoptosis
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
|
|
CNB-001 is a potent and orally active 5-lipoxygenase (5-LOX) inhibitor. CNB-001 can decreases 5-LOX expression and increase proteasome activity. CNB-001 can inhibit accumulation of soluble Amyloid-β and ubiquitinated aggregated proteins. CNB-001 can inhibit apoptosis, ROS production and stabilize mitochondrial membrane potential. CNB-001 can reduce insulin resistance and increase glucose uptake. CNB-001 also exhibits anti-ischemic, anti-inflammatory effects. CNB-001 can be used for the researches of inflammation, neurological and metabolic disease, such as Alzheimer's disease, stroke and diabetes .
|
-
- HY-168376
-
|
9(10)-Nitrated oleic acid
|
PPAR
ERK
Akt
NO Synthase
|
Metabolic Disease
Inflammation/Immunology
|
|
9 (10)-Nitrooleate (9(10)-Nitrated oleic acid) is an endogenous lipid signaling mediator with vasoprotective effects. 9 (10)-Nitrooleate enhances enzymatic activity and improves nitric oxide bioavailability by inducing phosphorylation of Akt and ERK1/2, regulating the multi-site phosphorylation status of eNOS and optimizing its interaction with Hsp90. 9 (10)-Nitrooleate also activates PPARα, PPARδ and PPARγ receptors, thereby regulating adipogenesis, glucose uptake and inflammation-related gene expression, and exhibits immunosuppressive effects by inhibiting neutrophil migration and cytokine secretion. 9 (10)-Nitrooleate is widely used in studies of sepsis and related inflammatory diseases .
|
-
- HY-N4150R
-
|
Quercetagetin-7-O-glucoside (Standard)
|
Reference Standards
Phosphatase
Tau Protein
NF-κB
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Quercetagitrin (Standard) is the analytical standard of Quercetagitrin. This product is intended for research and analytical applications. Quercetagitrin (Quercetagetin-7-O-glucoside) is a natural product that can be isolated from the African marigold (Tagetes erecta). Quercetagitrin has anti-inflammatory activity. Quercetagitrin inhibits Tau accumulation. Quercetagitrin can reverse neuroinflammation and cognitive deficits in P301S-Tau transgenic mouse model through inhibiting NF-κB activation. Quercetagitrin is a dual-target inhibitor of PTPN6 (IC50 = 1 μM) and PTPN9 (IC50 = 1.7 μM). Quercetagitrin enhances glucose uptake by mature C2C12 myoblasts. Quercetagitrin can be studied in research for Alzheimer’s disease and type 2 diabetes .
|
-
- HY-118241
-
|
|
Lactate Dehydrogenase
Bacterial
Apoptosis
Reactive Oxygen Species (ROS)
|
Cardiovascular Disease
Infection
Inflammation/Immunology
Cancer
|
|
GNE-140 is an orally active and selective inhibitor of lactate dehydrogenase (LDH) A, B and C, with IC50 values of 3, 5 and 5 nM against LDHA, LDHB, LDHC, respectively. GNE-140 blocks the conversion of pyruvate to lactate, reduces lactate production and histone lysine lactylation, and inhibits glycolysis. GNE-140 attenuates cardiac hypertrophy, alleviates PM2.5-induced pulmonary inflammation and fibrosis, blocks MRSA-induced Arg1 expression, regulates metabolites of glycolysis and the pentose phosphate pathway, reduces glucose uptake, increases ROS, and induces cancer cell apoptosis. GNE-140 is applicable to research related to pathological cardiac hypertrophy, pulmonary fibrosis, MRSA infection and pancreatic cancer .
|
-
- HY-115549
-
|
|
AMPK
Acetyl-CoA Carboxylase
|
Metabolic Disease
|
|
AMPK activator 18 is a potent allosteric activator of AMPK complexes containing the β2 isoform. AMPK activator 18activates α2-containing AMPK α2β2γ1 and α2β2γ3 complexes, with EC50 values of 17.2 and 82.1 nM. AMPK activator 18 stimulates β2-AMPK in cells, and glucose uptake by isolated skeletal muscle. AMPK activator 18 induces acetyl-coenzyme A carboxylase (ACC) and AMPK α-T172 phosphorylation. AMPK activator 18 can be used for the research of type 2 diabetes .
|
-
- HY-179578
-
|
|
Enolase
AMPK
Autophagy
Apoptosis
mTOR
Caspase
|
Metabolic Disease
Cancer
|
|
SU212 is a podophyllotoxin-derived ENO1 inhibitor and AMPK activator. SU212 can selectively induce oxidative phosphorylation, reduce glycolysis activity and glucose uptake in tumor cells, and directly bind to ENO1 without affecting these pathways in normal cells. SU212 induces apoptosis and promotes ENO1 degradation via proteasomal and autophagic pathways without inhibiting the catalytic activity. SU212 leads to mitotic arrest and apoptosis in TNBC (triple-negative breast cancer) cells by activating AMPK, demonstrating potent anti-tumor activity in vitro. SU212 inhibits tumor growth and metastasis in syngeneic, xenograft, and diabetic mouse models, exhibiting an excellent safety profile. SU212 can be used in research on t TNBC, diabetes, and fatty liver disease .
|
-
- HY-N18656
-
|
|
Bacterial
|
Infection
|
|
Terminalia chebula extract, derived from the fruit of the Terminalia chebula tree. Rich in bioactive compounds such as tannins, flavonoids, phenols, and organic acids like gallic acid and ellagic acid, this extract demonstrates a wide range of pharmacological activities. It acts as a natural laxative, supports digestive health, and exhibits potent antioxidant, anti-inflammatory, and antibacterial properties, effectively targeting various pathogenic bacteria, including Helicobacter pylori, Staphylococcus aureus, and Escherichia coli. Terminalia Chebula Extract also shows significant hepatoprotective effects, shielding the liver from damage through antioxidant and anti-inflammatory mechanisms. It has nephroprotective properties, alleviating renal dysfunction and enhancing kidney health by modulating inflammatory pathways. Additionally, the extract demonstrates neuroprotective activity, reducing neuronal damage and improving memory function. It has potential anti-diabetic effects, enhancing glucose uptake and reducing oxidative stress.
|
-
- HY-107207R
-
|
Kaempferol 3-O-neohesperidoside (Standard)
|
Reference Standards
Others
|
Metabolic Disease
|
|
Kaempferol 3-neohesperidoside (Kaempferol 3-O-neohesperidoside) Standard is the analytical standard of Kaempferol 3-neohesperidoside (HY-107207). This product is intended for research and analytical applications. Kaempferol 3-neohesperidoside (Kaempferol 3-O-neohesperidoside) is a flavonoid. Kaempferol 3-neohesperidoside mimics insulin action via the PI3K/PKC pathway, significantly promoting glucose uptake and increasing muscle glycogen content in rat soleus muscles. Kaempferol 3-neohesperidoside also exhibits anti-glycation activity. Kaempferol 3-neohesperidoside binds to albumin through hydrogen bonding and hydrophobic interactions, and inhibits the formation of advanced glycation end products. Kaempferol 3-neohesperidoside can be used in studies of diabetes and its related complications .
|
-
- HY-149255
-
|
|
Phosphatase
Aldose Reductase
|
Metabolic Disease
|
|
PTP1B/AKR1B1-IN-2 (Compound 7f) is a dual PTP1B/AKR1B1 inhibitor (IC50s: 3.2 and 2.1 μM, Kis: 4.0 and 0.9μM). PTP1B/AKR1B1-IN-2 is an insulin-mimetic agent. PTP1B/AKR1B1-IN-2 improves glucose uptake in murine C2C12 myoblasts. PTP1B/AKR1B1-IN-2 can be used for research of Type 2 diabetes mellitus (T2DM) .
|
-
- HY-178958
-
|
|
PPAR
Adenosine Receptor
Fatty Acid Synthase (FASN)
Endogenous Metabolite
|
Metabolic Disease
Inflammation/Immunology
Endocrinology
|
|
PPAR agonist 7 is an orally active pan-PPAR agonist, demonstrating potent activation of all three subtypes, PPARα (EC50 = 1.51 μM), PPARδ (EC50 = 1.11 μM), and PPARγ (EC50 = 3.14 μM). PPAR agonist 7 significantly enhances glucose uptake in adipocytes while exhibiting minimal adipogenic activity. PPAR agonist 7 can suppress PPARγ Ser273 phosphorylation in white adipose tissue and upregulate insulin-sensitizing genes. PPAR agonist 7 does not cause weight gain or fluid retention in high-fat diet (HFD)/
Streptozotocin (HY-13753) (STZ)-induced type 2 diabetes mellitus (T2DM) models. PPAR agonist 7 has selective modulation of PPAR signaling pathways without activation of adipogenic gene programs. PPAR agonist 7 can be used for the study of diabetes .
|
-
- HY-120657
-
|
|
CGRP Receptor
NF-κB
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
|
|
9-PAHSA is an orally active endogenous GPR120 agonist (EC50=18 μM). 9-PAHSA significantly inhibits LPS-induced inflammatory responses by blocking the NF-κB pathway. 9-PAHSA induces adipocyte browning, enhances glucose uptake and reduces lipid accumulation, while improving mitochondrial function and the survival rate of steatotic hepatocytes. In terms of neuroprotection, 9-PAHSA regulates the expression of REST and BDNF in the prefrontal cortex of diabetic mice, and effectively prevents spatial working memory deficits and abnormal social behaviors. 9-PAHSA does not directly regulate insulin secretion or improve systemic insulin sensitivity, and possesses specific anti-inflammatory, metabolic regulatory and neuroprotective properties. 9-PAHSA can be used in the research of diabetes-related cognitive impairment, obesity and non-alcoholic fatty liver disease .
|
-
- HY-P11043
-
|
|
GLP Receptor
Neuropeptide Y Receptor
Arrestin
|
Metabolic Disease
|
|
GEP44 is a peptide biased triple agonist targeting Glucagon-like peptide 1 receptor (GLP-1R), neuropeptide Y1 Receptor (Y1-R), and neuropeptide Y2 Receptor (Y2-R). GEP44 induces Y1-R antagonist-controlled, GLP-1R-dependent stimulation of insulin secretion in both rat and human pancreatic islets by counteracting effects of Y1-R and GLP-1R agonism. GEP44 promotes insulin-independent Y1-R-mediated glucose uptake in muscle tissue and significantly reduces food intake and body weight in diet-induced obese rat models. GEP44 can be used for obesity and type 2 diabetes mellitus research .
|
-
- HY-179631
-
|
|
Apoptosis
|
Cancer
|
|
2DG-ODDA is a 2-deoxyglucose (2-DG) (HY-13966) derivative with potent antitumor activity. 2DG-ODDA induces apoptosis, and reduces ATP production. 2DG-ODDA is taken up through both fatty acid and glucose transporters and is cleaved by α-Mannosidase (HY-P2950), releases 2DG to inhibit N-glycosylation and disrupt cellular metabolism. 2DG-ODDA inhibits tumor growth in a 4T1 mouse model. 2DG-ODDA can be used for the research of triple-negative breast cancer (TNBC) .
|
-
- HY-W770410
-
|
|
Isotope-Labeled Compounds
CGRP Receptor
NF-κB
|
Others
|
|
9-PAHSA- 13C4 is 13C-labeled 9-PAHSA. 9-PAHSAis an orally active endogenous GPR120 agonist (EC50=18 μM). 9-PAHSAsignificantly inhibits LPS-induced inflammatory responses by blocking the NF-κB pathway. 9-PAHSAinduces adipocyte browning, enhances glucose uptake and reduces lipid accumulation, while improving mitochondrial function and the survival rate of steatotic hepatocytes. In terms of neuroprotection, 9-PAHSAregulates the expression of REST and BDNF in the prefrontal cortex of diabetic mice, and effectively prevents spatial working memory deficits and abnormal social behaviors. 9-PAHSAdoes not directly regulate insulin secretion or improve systemic insulin sensitivity, and possesses specific anti-inflammatory, metabolic regulatory and neuroprotective properties. 9-PAHSAcan be used in the research of diabetes-related cognitive impairment, obesity and non-alcoholic fatty liver disease .
|
-
- HY-120657R
-
|
|
Reference Standards
CGRP Receptor
NF-κB
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Flumethrin (Standard) is the analytical standard of Flumethrin. This product is intended for research and analytical applications. 9-PAHSA is an orally active endogenous GPR120 agonist (EC50=18 μM). 9-PAHSA significantly inhibits LPS-induced inflammatory responses by blocking the NF-κB pathway. 9-PAHSA induces adipocyte browning, enhances glucose uptake and reduces lipid accumulation, while improving mitochondrial function and the survival rate of steatotic hepatocytes. In terms of neuroprotection, 9-PAHSA regulates the expression of REST and BDNF in the prefrontal cortex of diabetic mice, and effectively prevents spatial working memory deficits and abnormal social behaviors. 9-PAHSA does not directly regulate insulin secretion or improve systemic insulin sensitivity, and possesses specific anti-inflammatory, metabolic regulatory and neuroprotective properties. 9-PAHSA can be used in the research of diabetes-related cognitive impairment, obesity and non-alcoholic fatty liver disease .
|
-
- HY-144026S
-
|
|
CGRP Receptor
NF-κB
|
Inflammation/Immunology
|
|
9-PAHSA-d9 is the deuterium labeled 9-PAHSA (HY-120657). 9-PAHSA is an orally active endogenous GPR120 agonist (EC50=18 μM). 9-PAHSA significantly inhibits LPS-induced inflammatory responses by blocking the NF-κB pathway. 9-PAHSA induces adipocyte browning, enhances glucose uptake and reduces lipid accumulation, while improving mitochondrial function and the survival rate of steatotic hepatocytes. In terms of neuroprotection, 9-PAHSA regulates the expression of REST and BDNF in the prefrontal cortex of diabetic mice, and effectively prevents spatial working memory deficits and abnormal social behaviors. 9-PAHSA does not directly regulate insulin secretion or improve systemic insulin sensitivity, and possesses specific anti-inflammatory, metabolic regulatory and neuroprotective properties. 9-PAHSA can be used in the research of diabetes-related cognitive impairment, obesity and non-alcoholic fatty liver disease .
|
-
- HY-120657S
-
|
|
Isotope-Labeled Compounds
CGRP Receptor
NF-κB
|
Others
|
|
9-PAHSA-d4 is the deuterium labeled 9-PAHSA. 9-PAHSA is an orally active endogenous GPR120 agonist (EC50=18 μM). 9-PAHSA significantly inhibits LPS-induced inflammatory responses by blocking the NF-κB pathway. 9-PAHSA induces adipocyte browning, enhances glucose uptake and reduces lipid accumulation, while improving mitochondrial function and the survival rate of steatotic hepatocytes. In terms of neuroprotection, 9-PAHSA regulates the expression of REST and BDNF in the prefrontal cortex of diabetic mice, and effectively prevents spatial working memory deficits and abnormal social behaviors. 9-PAHSA does not directly regulate insulin secretion or improve systemic insulin sensitivity, and possesses specific anti-inflammatory, metabolic regulatory and neuroprotective properties. 9-PAHSA can be used in the research of diabetes-related cognitive impairment, obesity and non-alcoholic fatty liver disease .
|
-
- HY-120657S1
-
|
|
Isotope-Labeled Compounds
CGRP Receptor
NF-κB
|
Others
|
|
9-PAHSA-d31 is the deuterium labeled 9-PAHSA. 9-PAHSA is an orally active endogenous GPR120 agonist (EC50=18 μM). 9-PAHSA significantly inhibits LPS-induced inflammatory responses by blocking the NF-κB pathway. 9-PAHSA induces adipocyte browning, enhances glucose uptake and reduces lipid accumulation, while improving mitochondrial function and the survival rate of steatotic hepatocytes. In terms of neuroprotection, 9-PAHSA regulates the expression of REST and BDNF in the prefrontal cortex of diabetic mice, and effectively prevents spatial working memory deficits and abnormal social behaviors. 9-PAHSA does not directly regulate insulin secretion or improve systemic insulin sensitivity, and possesses specific anti-inflammatory, metabolic regulatory and neuroprotective properties. 9-PAHSA can be used in the research of diabetes-related cognitive impairment, obesity and non-alcoholic fatty liver disease .
|
-
- HY-N12060
-
|
|
Bcl-2 Family
Caspase
Apoptosis
Autophagy
Reactive Oxygen Species (ROS)
Akt
JNK
ERK
|
Cardiovascular Disease
Neurological Disease
|
|
Ginkgo biloba extract is a natural product that can be isolated from Ginkgo biloba leaves . Ginkgo biloba extract alleviates oxidative stress-induced neuronal apoptosis (Apoptosis) by stabilizing mitochondrial function, regulating Bcl-2 family proteins and inhibiting caspase activation. Ginkgo biloba extract alleviates testicular injury by upregulating SKP2 and inhibiting Beclin1-independent autophagy (Autophagy) . Ginkgo biloba extract alleviates various types of neuronal damage in animal models. Ginkgo biloba extract reduces behavioral sensitization in rats. Ginkgo biloba extract counteracts Aβ-induced neurotoxicity by blocking a series of Aβ-triggered events, including glucose uptake, ROS accumulation, AKT activation, mitochondrial dysfunction, JNK and ERK 1/2 pathways, and apoptosis, and also interferes with the formation of Aβ oligomers. Ginkgo biloba extract is applicable to research related to cerebral hypoperfusion, testicular injury, Alzheimer's disease, Parkinson's disease, multi-infarct dementia, stroke, traumatic brain injury and amyotrophic lateral sclerosis .
|
-
- HY-121811
-
|
Lanceolatin C
|
Glycosidase
Phosphatase
Interleukin Related
TNF Receptor
COX
Beclin1
GLUT
FAK
Akt
mTOR
p38 MAPK
Keap1-Nrf2
Apoptosis
Amyloid-β
Tau Protein
Autophagy
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Pongamol is an orally active flavonoid with an IC50 of 75 μM and a Ki of 58 μM against PTPase-1B, and an IC50 of 103.5 μM against intestinal α-Glycosidase. Pongamol reduces the release of IL‑1β, TNF‑α, COX‑2 and iNOS in cells, reverses the nuclear translocation of NF‑κB, and upregulates the levels of Beclin 1 and LC3 Ⅱ/LC3 Ⅰ. Pongamol promotes glucose uptake by increasing the level of GLUT4 on the surface of skeletal muscle cells. Pongamol inhibits epithelial-mesenchymal transition by suppressing the FAK/Akt-mTOR signaling pathway. Pongamol inhibits neuronal cytotoxicity, suppresses cell apoptosis and extends the lifespan of Caenorhabditis elegans by activating the MAPKs/Nrf2 signaling pathway. Pongamol exerts hypoglycemic effects in diabetic mouse models. Pongamol alleviates oxidative stress, neuroinflammation, Aβ deposition and excessive phosphorylation of Tau Protein, and restores autophagy function in Alzheimer's disease mouse models by inhibiting the Akt/mTOR signaling pathway. Pongamol is applicable to research related to Alzheimer's disease, type 2 diabetes, non-small cell lung cancer and postprandial hyperglycemia .
|
-
-
-
HY-L083
-
|
|
3,552 compounds
|
|
Mutations in oncogenes and tumor suppressor genes can modify multiple signaling pathways and in turn cell metabolism, which facilitates tumorigenesis. The paramount hallmark of tumor metabolism is “aerobic glycolysis” or the Warburg effect, coined by Otto Warburg in 1926, in which cancer cells produce most of energy from glycolysis pathway regardless of whether in aerobic or anaerobic condition. Usually, cancer cells are highly glycolytic (glucose addiction) and take up more glucose than do normal cells from outside. The increased uptake of glucose is facilitated by the overexpression of several isoforms of membrane glucose transporters (GLUTs). Likewise, the metabolic pathways of glutamine, amino acid and fat metabolism are also altered. Recent trends in anti-cancer drug discovery suggests that targeting the altered metabolic pathways of cancer cells result in energy crisis inside the cancer cells and can selectively inhibit cancer cell proliferation by delaying or suppressing tumor growth.
MCE provides a unique collection of 3,552 compounds which cover various tumor metabolism-related signaling pathways. These compounds can be used for anti-cancer metabolism targets identification, validation as well anti-cancer drug discovery.
|
| Cat. No. |
Product Name |
Type |
-
- HY-116215
-
|
|
Fluorescent Dyes
|
|
2-NBDG is a fluorescently-labeled deoxyglucose analog that is used primarily to directly monitor glucose uptake by living cells and tissues. It is also used as a topical contrast reagent for the detection of neoplasia. 2-NBDG can be used in real-time confocal, high-resolution, or wide-field fluorescence microscopy as well as in flow cytometry. The probe can be excited by the Argon laser at 488 nm to give the environment-sensitive fluorescence. It has lower photostability than the rhodamine-based fluorescent probes.
|
-
- HY-DY1019
-
|
|
Fluorescent Dyes
|
2-NBDG (solution) is a fluorescently-labeled deoxyglucose analog that is used primarily to directly monitor glucose uptake by living cells and tissues. It is also used as a topical contrast reagent for the detection of neoplasia. 2-NBDG can be used in real-time confocal, high-resolution, or wide-field fluorescence microscopy as well as in flow cytometry. The probe can be excited by the Argon laser at 488 nm to give the environment-sensitive fluorescence. It has lower photostability than the rhodamine-based fluorescent probes. Solvent and Concentration: Sterile PBS: 5 mM
|
-
- HY-113870
-
|
|
Fluorescent Dyes
|
|
6-NBDG is a fluorescent glucose analogue, it can be used for fluorescence imaging and monitoring glucose transport and uptake. 6-NBDG can be used as a fluorescent probe for detecting macrophage-rich atherosclerotic plaques .
|
-
- HY-D2433
-
|
|
Fluorescent Dyes
|
|
Glucose-PEG2000-Cy3 is a Cy3 (HY-D0822) labeled Glucose-PEG conjugate. The Cy3 fluorophore is commonly used in applications such as immunolabeling, nucleic acid labeling, fluorescence microscopy, and flow cytometry. Cy3 has an emission maximum around 562-570 nm. Glucose-PEG improves drug cellular uptake and reduces endosomal degradation, and can be used in drug delivery .
|
-
- HY-D3199
-
|
|
Fluorescent Dyes
|
|
NIR-fluorescent glucose is a functional glucose-based fluorescent imaging agent. Conjugated with the nitrobenzoselenadiazole-based SCOTfluor (compound 9), NIR-fluorescent glucose acts as a substrate for GLUT4 and GLUT2 transporters. NIR-fluorescent glucose enables the visualization of glucose uptake in live cells and in vivo .
|
-
- HY-D3196
-
|
|
Fluorescent Dyes
|
|
AG2 is a glucose uptake tracer and two-photon fluorescent probe. AG2 is taken up by cells via glucose-specific transport systems, rather than passive diffusion; it preferentially accumulates in cancer cells and colon cancer tissues compared with normal cells and tissues; it mainly localizes to mitochondria, with a small amount also distributed in the cytoplasm and cell membrane. AG2 can be used for colon cancer research .
|
| Cat. No. |
Product Name |
Type |
-
- HY-W134327A
-
|
Diethylaminoethyl dextran (MW 500000)
|
Biochemical Assay Reagents
|
|
DEAE-Dextran (MW 500000) is a complex carbohydrate polymer consisting of glucose molecules linked by glycosidic bonds and modified with diethylaminoethyl (DEAE) groups. DEAE-Dextran is a cationic molecule that can be used as a transfection reagent to deliver nucleic acids such as DNA or RNA into cells. Its positive charge interacts with negatively charged cell membranes, facilitating the uptake of nucleic acids. DEAE-Dextran can also be used as an ion-exchange chromatography resin, allowing the separation and purification of biomolecules based on their charge.
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-137874
-
|
|
Peptides
|
Metabolic Disease
Cancer
|
|
L-Glutamic γ-monohydroxamate is an antitumor agent, inhibits cell proliferation. L-Glutamic γ-monohydroxamate selectively inhibits the uptake of L-histidine into microvascular endothelial cell. L-Glutamic γ-monohydroxamate, as a vanadium ligand, activates glucose uptake and metabolism, thus decreases the blood glucose levels in vivo .
|
-
- HY-P1473
-
|
Amylin (8-37) (mouse, rat)
|
Amylin Receptor
|
Metabolic Disease
|
|
Amylin (8-37), rat is a truncated analog of native Amylin that selectively inhibits insulin-related glucose uptake and glycogen deposition in muscle tissue. Amylin (8-37), rat is a weak amylin receptor (AMY) antagonist.
|
-
- HY-P10230
-
|
|
Bacterial
|
Infection
|
|
Sublancin is an antimicrobial peptide, which inhibits DNA replication, transcription and translation, without affecting membrane integrity. Sublancin suppresses glucose uptake for the competition of phosphotransferase system (PTS). Sublancin inhibits B. subtilis strain 168 ΔSPβ with MIC of 0.312 μM .
|
-
- HY-P11043
-
|
|
GLP Receptor
Neuropeptide Y Receptor
Arrestin
|
Metabolic Disease
|
|
GEP44 is a peptide biased triple agonist targeting Glucagon-like peptide 1 receptor (GLP-1R), neuropeptide Y1 Receptor (Y1-R), and neuropeptide Y2 Receptor (Y2-R). GEP44 induces Y1-R antagonist-controlled, GLP-1R-dependent stimulation of insulin secretion in both rat and human pancreatic islets by counteracting effects of Y1-R and GLP-1R agonism. GEP44 promotes insulin-independent Y1-R-mediated glucose uptake in muscle tissue and significantly reduces food intake and body weight in diet-induced obese rat models. GEP44 can be used for obesity and type 2 diabetes mellitus research .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-N0457
-
-
-
- HY-W040127
-
-
-
- HY-N0466
-
-
-
- HY-N12060
-
|
|
Structural Classification
Natural Products
Ginkgoaceae
Plants
Ginkgo biloba
Source Classification
|
Bcl-2 Family
Caspase
Apoptosis
Autophagy
Reactive Oxygen Species (ROS)
Akt
JNK
ERK
|
|
Ginkgo biloba extract is a natural product that can be isolated from Ginkgo biloba leaves . Ginkgo biloba extract alleviates oxidative stress-induced neuronal apoptosis (Apoptosis) by stabilizing mitochondrial function, regulating Bcl-2 family proteins and inhibiting caspase activation. Ginkgo biloba extract alleviates testicular injury by upregulating SKP2 and inhibiting Beclin1-independent autophagy (Autophagy) . Ginkgo biloba extract alleviates various types of neuronal damage in animal models. Ginkgo biloba extract reduces behavioral sensitization in rats. Ginkgo biloba extract counteracts Aβ-induced neurotoxicity by blocking a series of Aβ-triggered events, including glucose uptake, ROS accumulation, AKT activation, mitochondrial dysfunction, JNK and ERK 1/2 pathways, and apoptosis, and also interferes with the formation of Aβ oligomers. Ginkgo biloba extract is applicable to research related to cerebral hypoperfusion, testicular injury, Alzheimer's disease, Parkinson's disease, multi-infarct dementia, stroke, traumatic brain injury and amyotrophic lateral sclerosis .
|
-
-
- HY-N2486
-
-
-
- HY-N1511
-
-
-
- HY-N4150
-
-
-
- HY-N5083
-
-
-
- HY-126411
-
-
-
- HY-N6258
-
-
-
- HY-N2040
-
-
-
- HY-N0642
-
-
-
- HY-107207
-
-
-
- HY-N4095
-
-
-
- HY-N8438
-
-
-
- HY-N2209
-
-
-
- HY-N7676
-
-
-
- HY-120657
-
|
|
Structural Classification
Classification of Application Fields
Ketones, Aldehydes, Acids
Other Diseases
Endogenous metabolite
Disease Research Fields
Source Classification
|
CGRP Receptor
NF-κB
|
|
9-PAHSA is an orally active endogenous GPR120 agonist (EC50=18 μM). 9-PAHSA significantly inhibits LPS-induced inflammatory responses by blocking the NF-κB pathway. 9-PAHSA induces adipocyte browning, enhances glucose uptake and reduces lipid accumulation, while improving mitochondrial function and the survival rate of steatotic hepatocytes. In terms of neuroprotection, 9-PAHSA regulates the expression of REST and BDNF in the prefrontal cortex of diabetic mice, and effectively prevents spatial working memory deficits and abnormal social behaviors. 9-PAHSA does not directly regulate insulin secretion or improve systemic insulin sensitivity, and possesses specific anti-inflammatory, metabolic regulatory and neuroprotective properties. 9-PAHSA can be used in the research of diabetes-related cognitive impairment, obesity and non-alcoholic fatty liver disease .
|
-
-
- HY-N7912
-
-
-
- HY-121811
-
|
Lanceolatin C
|
Structural Classification
Pongamia pinnata (L.) Pierre
Leguminosae
Ketones, Aldehydes, Acids
Derris trifoliata Lour.
Plants
Source Classification
|
Glycosidase
Phosphatase
Interleukin Related
TNF Receptor
COX
Beclin1
GLUT
FAK
Akt
mTOR
p38 MAPK
Keap1-Nrf2
Apoptosis
Amyloid-β
Tau Protein
Autophagy
|
|
Pongamol is an orally active flavonoid with an IC50 of 75 μM and a Ki of 58 μM against PTPase-1B, and an IC50 of 103.5 μM against intestinal α-Glycosidase. Pongamol reduces the release of IL‑1β, TNF‑α, COX‑2 and iNOS in cells, reverses the nuclear translocation of NF‑κB, and upregulates the levels of Beclin 1 and LC3 Ⅱ/LC3 Ⅰ. Pongamol promotes glucose uptake by increasing the level of GLUT4 on the surface of skeletal muscle cells. Pongamol inhibits epithelial-mesenchymal transition by suppressing the FAK/Akt-mTOR signaling pathway. Pongamol inhibits neuronal cytotoxicity, suppresses cell apoptosis and extends the lifespan of Caenorhabditis elegans by activating the MAPKs/Nrf2 signaling pathway. Pongamol exerts hypoglycemic effects in diabetic mouse models. Pongamol alleviates oxidative stress, neuroinflammation, Aβ deposition and excessive phosphorylation of Tau Protein, and restores autophagy function in Alzheimer's disease mouse models by inhibiting the Akt/mTOR signaling pathway. Pongamol is applicable to research related to Alzheimer's disease, type 2 diabetes, non-small cell lung cancer and postprandial hyperglycemia .
|
-
-
- HY-N2486R
-
-
-
- HY-N8540
-
|
|
Natural Products
Microorganisms
Source Classification
|
Phosphoglycerate Kinase (PGK)
Fungal
Apoptosis
|
|
Ilicicolin H is a selective and non-ATP-competitive phosphoglycerate kinase 1 (PGK1) (IC50 = 9.02 μM) and mitochondrial cytochrome bc1 reductase (IC50 = 2-3 ng/mL) inhibitor. Ilicicolin H directly binds to PGK1 with KD of 60 μM .Ilicicolin H can inhibit cell proliferation and induce apoptosis. Ilicicolin H can inhibit the lactate production and glucose uptake of hepatocellular carcinoma (HCC) cells. Ilicicolin H has a broad antifungal spectrum including C. albicans, Cryptococcus and A. fumigatus. Ilicicolin H can be used for the researches of cancer and infection, such as hepatocellular carcinoma (HCC) and C. albicans infection .
|
-
-
- HY-N1185
-
-
-
- HY-N3426
-
-
-
- HY-N7605
-
-
-
- HY-142088
-
|
|
Natural Products
Microorganisms
Source Classification
|
Endogenous Metabolite
|
|
Beauverolide Ka, a cyclotetradepsipeptide, is a metabolite of Beauveria bassiana fungus. Beauverolide Ka stimulates glucose uptake in cultured rat L6 myoblasts at 50 μM. Beauverolide Ka exhibits protecting effects on HEI-OC1 cells at 10 μM and shows dose-dependent activity in both L6 myoblasts and myotubes .
|
-
-
- HY-N0457R
-
-
-
- HY-N0466R
-
|
|
Structural Classification
Trifolium hybridum L.
Terpenoids
Diterpenoids
Plants
Compositae
Endogenous metabolite
Source Classification
|
Reference Standards
Glycosidase
HMG-CoA Reductase (HMGCR)
Fatty Acid Synthase (FASN)
LDLR
|
|
Rebaudioside A (Standard) is the analytical standard of Rebaudioside A. This product is intended for research and analytical applications. Rebaudioside A is an orally effective steviol glycoside with high sweetness. Rebaudioside A acts as an inhibitor of α-glucosidase with an IC50 value of 35.01 μg/mL. Rebaudioside A increases the ATP/ADP ratio in β cells in a glucose-dependent manner, thereby inhibiting KATP channels, leading to membrane depolarization, calcium influx, and ultimately stimulating insulin secretion. Rebaudioside A activates the SREBP signaling pathway by inhibiting HMGCR, the rate-limiting enzyme in cholesterol synthesis, resulting in increased expression of LDLR on the cell surface, thus promoting the uptake of LDL-C in the blood. Rebaudioside A can be used for studies on blood glucose and lipid regulation as well as anti-obesity.
|
-
-
- HY-N5123
-
-
-
- HY-N8490
-
-
-
- HY-W411439
-
-
-
- HY-146036
-
-
-
- HY-N16431
-
|
|
Natural Products
Microorganisms
Source Classification
|
AMPK
Nuclear Factor of activated T Cells (NFAT)
Interleukin Related
Endogenous Metabolite
|
|
NFAT-133 is an aromatic polyketide with immunosuppressive and antidiabetic activity. NFAT-133 activates the AMPK pathway, promoting glucose uptake in L6 muscle fibers, thereby resisting diabetes. NFAT-133 inhibits the transcriptional activity of activated T-cell nuclear factor (NFAT), thereby suppressing the expression of IL-2 and the proliferation of T cells, demonstrating an immunosuppressive effect. NFAT-133 does not exhibit antibacterial activity or cytotoxicity, but it can weaken the production of NO in RAW264.7 cells induced by Lipopolysaccharide (LPS) (HY-D1056) .
|
-
-
- HY-N5083R
-
-
-
- HY-N6258R
-
-
-
- HY-N1511R
-
|
|
Triterpenes
Structural Classification
Terpenoids
Polyporaceae
Ganoderma lucidum (Leyss. Ex Fr.) Karst.
Plants
|
Reference Standards
Sirtuin
Apoptosis
|
|
Ganoderic acid D (Standard) is the analytical standard of Ganoderic acid D. This product is intended for research and analytical applications. Ganoderic acid D, a highly oxygenated tetracyclic triterpenoid, is the major active component of Ganoderma lucidum. Ganoderic acid D upregulates the protein expression of SIRT3 and induces the deacetylated cyclophilin D (CypD) by SIRT3. Ganoderic acid D inhibits the energy reprogramming of colon cancer cells including glucose uptake, lactate production, pyruvate and acetyl-coenzyme production in colon cancer cells . Ganoderic acid D induces HeLa human cervical carcinoma apoptosis .
|
-
-
- HY-N4095R
-
-
-
- HY-N3055
-
|
|
Cupressaceae
Classification of Application Fields
Terpenoids
Diterpenoids
Plants
Disease Research Fields
Calocedrus decurrens (Torr.) Florin
Source Classification
Cancer
|
Apoptosis
AMPK
Platelet-activating Factor Receptor (PAFR)
Caspase
|
|
Pinusolide is an AMPK activator and PAF receptor antagonist. Pinusolide activates AMPK, phosphorylates ACC, enhances IRS-1 tyrosine phosphorylation, boosts glucose uptake, and modulates insulin signaling. Pinusolide inhibits caspase-3/7 activation, intracellular calcium elevation, reactive oxygen species overproduction, lipid peroxidation, and tumor cell proliferation. Pinusolide stabilizes superoxide dismutase activity, reduces apoptotic hallmarks, induces mitochondrial pathway apoptosis, and triggers DNA fragmentation. Pinusolide can be used for the research of type 2 diabetes, neurodegenerative diseases, acute lymphoblastic leukemia, acute myeloid leukemia, and Burkitt lymphoma .
|
-
-
- HY-N4150R
-
|
Quercetagetin-7-O-glucoside (Standard)
|
Flavonols
Structural Classification
Flavonoids
Erythrina melanacantha Taub. ex Harms
Phenols
Polyphenols
Plants
Compositae
Source Classification
|
Reference Standards
Phosphatase
Tau Protein
NF-κB
|
|
Quercetagitrin (Standard) is the analytical standard of Quercetagitrin. This product is intended for research and analytical applications. Quercetagitrin (Quercetagetin-7-O-glucoside) is a natural product that can be isolated from the African marigold (Tagetes erecta). Quercetagitrin has anti-inflammatory activity. Quercetagitrin inhibits Tau accumulation. Quercetagitrin can reverse neuroinflammation and cognitive deficits in P301S-Tau transgenic mouse model through inhibiting NF-κB activation. Quercetagitrin is a dual-target inhibitor of PTPN6 (IC50 = 1 μM) and PTPN9 (IC50 = 1.7 μM). Quercetagitrin enhances glucose uptake by mature C2C12 myoblasts. Quercetagitrin can be studied in research for Alzheimer’s disease and type 2 diabetes .
|
-
-
- HY-107207R
-
|
Kaempferol 3-O-neohesperidoside (Standard)
|
Flavonols
Structural Classification
Flavonoids
Typhaceae
Typha orientalis Presl
Phenols
Polyphenols
Plants
Source Classification
|
Reference Standards
Others
|
|
Kaempferol 3-neohesperidoside (Kaempferol 3-O-neohesperidoside) Standard is the analytical standard of Kaempferol 3-neohesperidoside (HY-107207). This product is intended for research and analytical applications. Kaempferol 3-neohesperidoside (Kaempferol 3-O-neohesperidoside) is a flavonoid. Kaempferol 3-neohesperidoside mimics insulin action via the PI3K/PKC pathway, significantly promoting glucose uptake and increasing muscle glycogen content in rat soleus muscles. Kaempferol 3-neohesperidoside also exhibits anti-glycation activity. Kaempferol 3-neohesperidoside binds to albumin through hydrogen bonding and hydrophobic interactions, and inhibits the formation of advanced glycation end products. Kaempferol 3-neohesperidoside can be used in studies of diabetes and its related complications .
|
-
-
- HY-120657R
-
|
|
Structural Classification
Ketones, Aldehydes, Acids
Endogenous metabolite
Source Classification
|
Reference Standards
CGRP Receptor
NF-κB
|
|
Flumethrin (Standard) is the analytical standard of Flumethrin. This product is intended for research and analytical applications. 9-PAHSA is an orally active endogenous GPR120 agonist (EC50=18 μM). 9-PAHSA significantly inhibits LPS-induced inflammatory responses by blocking the NF-κB pathway. 9-PAHSA induces adipocyte browning, enhances glucose uptake and reduces lipid accumulation, while improving mitochondrial function and the survival rate of steatotic hepatocytes. In terms of neuroprotection, 9-PAHSA regulates the expression of REST and BDNF in the prefrontal cortex of diabetic mice, and effectively prevents spatial working memory deficits and abnormal social behaviors. 9-PAHSA does not directly regulate insulin secretion or improve systemic insulin sensitivity, and possesses specific anti-inflammatory, metabolic regulatory and neuroprotective properties. 9-PAHSA can be used in the research of diabetes-related cognitive impairment, obesity and non-alcoholic fatty liver disease .
|
-
-
- HY-N18033
-
-
-
- HY-N17773
-
|
|
Structural Classification
Monophenols
Hydrangeaceae
Phenols
Plants
Source Classification
|
PPAR
GLUT
TNF Receptor
|
|
Hydrangeic acid is an orally effective stilbene-type glycolipid metabolism regulator that lowers blood glucose and lipids. It can be isolated from processed leaves of Hydrangea macrophylla var. thunbergii. Hydrangeic acid is associated with glycolipid metabolism and insulin sensitivity regulation. Hydrangeic acid does not directly activate PPARγ or PPARα, but instead upregulates the mRNA expression of adiponectin, PPARγ2, GLUT4, and fatty acid-binding protein aP2, and downregulates TNF-α mRNA expression, promoting adipogenesis, glucose uptake, and GLUT4 translocation in 3T3-L1 cells. Simultaneously, Hydrangeic acid inhibits inflammatory factor-induced NO production, exerting activity in improving insulin resistance. Hydrangeic acid can be used in research related to type 2 diabetes and does not cause liver weight gain as a side effect.
|
-
-
- HY-N17326
-
-
-
- HY-N18656
-
|
|
Structural Classification
Extract
|
Bacterial
|
|
Terminalia chebula extract, derived from the fruit of the Terminalia chebula tree. Rich in bioactive compounds such as tannins, flavonoids, phenols, and organic acids like gallic acid and ellagic acid, this extract demonstrates a wide range of pharmacological activities. It acts as a natural laxative, supports digestive health, and exhibits potent antioxidant, anti-inflammatory, and antibacterial properties, effectively targeting various pathogenic bacteria, including Helicobacter pylori, Staphylococcus aureus, and Escherichia coli. Terminalia Chebula Extract also shows significant hepatoprotective effects, shielding the liver from damage through antioxidant and anti-inflammatory mechanisms. It has nephroprotective properties, alleviating renal dysfunction and enhancing kidney health by modulating inflammatory pathways. Additionally, the extract demonstrates neuroprotective activity, reducing neuronal damage and improving memory function. It has potential anti-diabetic effects, enhancing glucose uptake and reducing oxidative stress.
|
-
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-W770410
-
|
|
|
9-PAHSA- 13C4 is 13C-labeled 9-PAHSA. 9-PAHSAis an orally active endogenous GPR120 agonist (EC50=18 μM). 9-PAHSAsignificantly inhibits LPS-induced inflammatory responses by blocking the NF-κB pathway. 9-PAHSAinduces adipocyte browning, enhances glucose uptake and reduces lipid accumulation, while improving mitochondrial function and the survival rate of steatotic hepatocytes. In terms of neuroprotection, 9-PAHSAregulates the expression of REST and BDNF in the prefrontal cortex of diabetic mice, and effectively prevents spatial working memory deficits and abnormal social behaviors. 9-PAHSAdoes not directly regulate insulin secretion or improve systemic insulin sensitivity, and possesses specific anti-inflammatory, metabolic regulatory and neuroprotective properties. 9-PAHSAcan be used in the research of diabetes-related cognitive impairment, obesity and non-alcoholic fatty liver disease .
|
-
-
- HY-120657S
-
|
|
|
9-PAHSA-d4 is the deuterium labeled 9-PAHSA. 9-PAHSA is an orally active endogenous GPR120 agonist (EC50=18 μM). 9-PAHSA significantly inhibits LPS-induced inflammatory responses by blocking the NF-κB pathway. 9-PAHSA induces adipocyte browning, enhances glucose uptake and reduces lipid accumulation, while improving mitochondrial function and the survival rate of steatotic hepatocytes. In terms of neuroprotection, 9-PAHSA regulates the expression of REST and BDNF in the prefrontal cortex of diabetic mice, and effectively prevents spatial working memory deficits and abnormal social behaviors. 9-PAHSA does not directly regulate insulin secretion or improve systemic insulin sensitivity, and possesses specific anti-inflammatory, metabolic regulatory and neuroprotective properties. 9-PAHSA can be used in the research of diabetes-related cognitive impairment, obesity and non-alcoholic fatty liver disease .
|
-
-
- HY-167857S
-
|
|
|
Glutathione Disulfide- 13C4, 15N2 is the 13C- and 15N-labeled (Rac)-Glutipyran (HY-167857). (Rac)-Glutipyran is a broad-spectrum GLUT inhibitor that targets both GLUT1 and GLUT3. (Rac)-Glutipyran inhibits glucose uptake and suppresses the growth of multiple cancer cells, significantly inhibiting PANC-1 cell growth (IC50=1.8 μM) and glucose uptake (IC50=0.13 μM) .
|
-
-
- HY-144026S
-
|
|
|
9-PAHSA-d9 is the deuterium labeled 9-PAHSA (HY-120657). 9-PAHSA is an orally active endogenous GPR120 agonist (EC50=18 μM). 9-PAHSA significantly inhibits LPS-induced inflammatory responses by blocking the NF-κB pathway. 9-PAHSA induces adipocyte browning, enhances glucose uptake and reduces lipid accumulation, while improving mitochondrial function and the survival rate of steatotic hepatocytes. In terms of neuroprotection, 9-PAHSA regulates the expression of REST and BDNF in the prefrontal cortex of diabetic mice, and effectively prevents spatial working memory deficits and abnormal social behaviors. 9-PAHSA does not directly regulate insulin secretion or improve systemic insulin sensitivity, and possesses specific anti-inflammatory, metabolic regulatory and neuroprotective properties. 9-PAHSA can be used in the research of diabetes-related cognitive impairment, obesity and non-alcoholic fatty liver disease .
|
-
-
- HY-120657S1
-
|
|
|
9-PAHSA-d31 is the deuterium labeled 9-PAHSA. 9-PAHSA is an orally active endogenous GPR120 agonist (EC50=18 μM). 9-PAHSA significantly inhibits LPS-induced inflammatory responses by blocking the NF-κB pathway. 9-PAHSA induces adipocyte browning, enhances glucose uptake and reduces lipid accumulation, while improving mitochondrial function and the survival rate of steatotic hepatocytes. In terms of neuroprotection, 9-PAHSA regulates the expression of REST and BDNF in the prefrontal cortex of diabetic mice, and effectively prevents spatial working memory deficits and abnormal social behaviors. 9-PAHSA does not directly regulate insulin secretion or improve systemic insulin sensitivity, and possesses specific anti-inflammatory, metabolic regulatory and neuroprotective properties. 9-PAHSA can be used in the research of diabetes-related cognitive impairment, obesity and non-alcoholic fatty liver disease .
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-173115
-
|
|
|
Alkynes
|
|
15-LOX-IN-2 (Compound 2a) is an orally active COX-2/15-LOX inhibitor and a partial agonist of PPARγ. 15-LOX-IN-2 has anti-inflammatory activity and inhibits the levels of 20-HETE, IL-1β and TNF-α in RAW 264.7 cells treated with LPS (HY-D1056). In addition, 15-LOX-IN-2 has significant glucose uptake capacity in the absence of insulin. 15-LOX-IN-2 can be used for the research of metabolic diseases .
|
| Cat. No. |
Product Name |
|
Classification |
-
- HY-174700
-
|
|
|
mRNA
|
|
Human FGF21 mRNA encodes the human fibroblast growth factor 21 (FGF21) protein, a member of the fibroblast growth factor (FGF) family. FGF21 is a secreted endocrine factor that functions as a major metabolic regulator. It stimulates the uptake of glucose in adipose tissue.
|
-
- HY-174687
-
|
|
|
mRNA
|
|
Human FGFR4 mRNA encodes the human fibroblast growth factor receptor 4 (FGFR4) protein, a tyrosine kinase and cell surface receptor for fibroblast growth factors. FGFR4 is involved in the regulation of several pathways, including cell proliferation, cell differentiation, cell migration, lipid metabolism, bile acid biosynthesis, vitamin D metabolism, glucose uptake, and phosphate homeostasis.
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: